Official Title of Study:  
 
A Phase 2 Randomized, Double- Blind, Placebo- Controlled Study to Evaluate Efficacy and  
Safety of BMS -986165 in Subjects with Systemic Lupus Erythematosus  
 
Study ID: [REMOVED] 
 
Document Date (Date in which document was last revised): A pril 15, 2020  
Protocol Number: IM011021
IND Number: [ADDRESS_35340] Number: 2017-001203-79
Date; Version: 15-Apr-2020; IM011021 ‚ÄìRevised Protocol 04 Final Approved
Clinical Protocol IM011021
A Phase 2 Randomized, Double-Bl ind, Placebo-Controlled Study to  Evaluate Efficacy and 
Safety of BMS-986165 in Subjects with Systemic Lupus Erythemato sus
24-hr Emergency Telephone Number
North America: 
Asia-Pacific: 
Bristol-Myers Squibb Research and Development
[ADDRESS_35341] de Finlande 4
B-1420 Braine- l‚ÄôAlleud, Belgium
6-5-1 Nishi-Shinjuku, Shinjuku-ku,
Tokyo, 163-1328, Japan
This document is the confidential and proprietary information o f Bristol-Myers Squibb C ompany and its global 
affiliates (BMS). By [CONTACT_35826], you agree to keep  it confidential and to use and disclose it solely 
for the purpose of assessing whether your organization will participate in and/or the performance of the 
proposed BMS sponsored study. Any permitted disclosures will be  made only on a confidential "need to know" 
basis within your organization or to your independent ethics co mmittee(s). Any other use, copying, disclosure 
or dissemination of this information is strictly prohibited unl ess expressly authorized in writing by [CONTACT_20444]. Any 
supplemental information (eg, amendments) that may be added to this document is also confidential and 
proprietary to BMS and must be kep t in confidence in the same m anner as the contents of this document. Any 
person who receives this document without due authorization fro m BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to B MS in this protocol may apply to partners to 
which BMS has transferred obligations, eg, a Contract Research Organization.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 2DOCUMENT HISTORY
Document Date of Issue Approver(s) Summary of Change
Original Protocol 23-May- 2017 Not applicable
Japan Protocol 
Amendment 0123-Aug- 2017 Japan specific
Global
Revision 01 
(Version 2.0)24-Jan-2018 Updated the Sponsor‚Äôs protocol 
template, style, and made typographic 
corrections throughout the protocol; 
revised study design including sample 
size reductio n to 360, decreased 
frequency of 12 mg arm to QD, and 
changed primary objective to SRI(4) response; clarified and updated certain procedures; revised certain inclusion/exclusion for clarity; revised 
certain appendices based on updates 
throughout Innovative
Medicines 
Development
Japan Protocol 
Amendment 0228-Mar- 2018 Japan specific
Japan Protocol 
Amendment 0326-Jun- 2018 Japan specific
Global
Revision 02
(Version 3.0)28-Jan-2019 Updated the Sponsor‚Äôs contact 
[CONTACT_35827]; made typographic 
corrections to the protocol; clarified 
certain procedures; changed LLDAS 
 to a secondary 
endpoint; redefined partial and major 
clinical response; revised certain 
inclusion/exclusion criteria for clarity; 
updated word ing in Appendix 3 and 
Appendix 4  to be consistent across 
studies of BMS -986165
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 3Document Date of Issue Approver(s) Summary of Change
Global
Revision 03
(Version 4.0)11-Jun-2019 Updated the Document History to 
include several Japan -specific 
amendments
Restored the Photography assessment 
inTable 3 (Week 28/Day197 Visit), 
which was inadvertently omitted in 
v3.0 
 
 
Clarified Inclusion Criteria regarding: 
xLoss of functional range of
movements and daily activity
(SLE Disease Characteristics in
Inclusion Criterion 2)e)ii);
Section 5.1 )
xUse of corticosteroid
monotherapy (Medications for
SLE in Inclusion Criterion 3)b);
Section 5.1 )
xUse of effective methods ofcontraception (Age and
Reproductive Status in Inclusion
Criterion 4)f) and 4)g);
Section 5.1 )
Removed langua ge regarding 
prohibition of P -glycoprotein 
inhibitors (item #7, Section 6.7.1 )
based on recent drug- drug interaction 
data 
Revised the definition of an overdose 
to align with a revision of appendices across IMD; overdose is no longer reported automatically as a serious adverse event ( Section 
8.4)
 
 
Clarified that plasma concentration values (rather than just Ctrough 
values) will be summarized 
(Section
[IP_ADDRESS])
Aligned  APPENDIX 4 language 
regarding male subjects with female partner(s) of childbearing potential with current safety guidance. 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 4Document Date of Issue Approver(s) Summary of Change
Protocol 
Amendment 07a30-Jul- 2019 South Korea and Taiwan -specific 
amendment to modify inclusion 
criterion regarding age and to include hepatitis B surface antibody screening and hepatitis B virus DNA screening and monitoring.
Global
Revision 0 4
im011021 -
revprot04b15-Apr-2020 Updated the Study Director and 
Approver information;  
 
 clarifie
d PK sampling 
windows; synchronized sample size 
determination with testing hierarchy; updated adjustments for multiplicity.
aRevision numbering has been updated to reflect total number of revisions.
bProtocol numbering format has been updated. Legacy  numberin g is provided for consistency.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 5SUMMARY OF CHANGES
Rationale: 
The primary purpose of this global revised protocol is to modif y the analysis plan and provide 
clarifications in the protocol.Key modifications and clarifications are summarized as follows:  
xAdded clarifying detail to several items in the protocol
xChanged secondary endpoints to be assessed at 48 weeks
xUpdated the sampling windows for the collection of pharmacokine tic samples at the Day 1
and Day 85 visits
xRevised certain sub-sections within Statistical Considerations
Substantive changes made to previous versions of the protocol a nd the rationale for these changes 
are noted below in the summary of key changes table. All change s applied to the protocol body 
were applied to the synopsis, as necessary; synopsis changes ar e not included in the summary of 
key changes table. Only major additions and deletions are provi ded in this summary table; all 
minor grammatical, formatting, stylis tic changes, or clarificat ions as well as organizational 
changes are not included.
SUMMARY OF KEY CHANGES TO THE REVISED PROTOCOL
Section Number 
& TitleDescription of Change Brief Rationale
Title Page Updated sponsor Study DirectorUpdated with current 
contact
[CONTACT_35828] 
(listed below)Rationale for changes 
included below
3 Objectives and 
Endpoints ;Table
7Revised description of pharmacokinetic sobjective and endpointClarified that the 
active metabolite of 
BMS -986165 is 
included in the 
analysis
3 Objectives and 
Endpoints ,
[IP_ADDRESS] EndpointsMoved Week 48 endpoints (SR I(4), BICLA, LLDAS, CLASI50,
and 40 -Joint count) to multiplicity-controlled Secondary 
Endpoints (and correspo nding Secondary Objectives)
 Week 48 endpoints 
moved into the 
multiplicity -controlled 
hierarchy for better 
alignment with regulatory guidance documents
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 6SUMMARY OF KEY CHANGES TO THE REVISED PROTOCOL
Section Number 
& TitleDescription of Change Brief Rationale
4.1Overall 
DesignRemoved the following sentence:
The end of the study for sample a nalysis is defined as 2 years a fter 
final clinical study reportTo remove 
inconsistency as future 
sample analysis may 
be up to 15 years after the final clinical study report or as per local regulations
5.1Inclusion 
CriteriaRemoved criterion 4 i)For consistency with 
male contraception 
requirements
5.5.1 Retesting 
During Screening  
Period; RescreeningUpdated text for rescreening subjectsAdditional rescreening 
is allowed for subjects who may be otherwise eligible but experience an exceptional 
circumstance beyond 
site or subject control.
8.6.2 Sampling 
WindowsUpdated to:
‚Ä¢The following windows apply to oth er samples:
- ¬±0.25 hour for the 0.5-hour sample
- ¬±0.5 hour for the 2-hour sample
- ¬±1 hour for the 4- and 6-hour samplesAdded a 
pharmacokinetic sampling window for the 0.5
-hour collection 
(Day 1 and Day 85) 
and modified the 2-
hour collection window (Day 1 and 
Day 85)
8.6.2 Sampling 
WindowsUpdated to:
If samples cannot be taken wit hin the specified time window, 
every effort should be mad e to take a sample as soon as
possible. Deviations from the sampling windows must be noted 
in the source documents.To instruct sites to 
collect samples even if 
they are collected 
outside of the provided sample windows and document these occurrences.
9.1 Sample Size 
DeterminationUpdated text to include description of the BID and QD branchesThe power for the 
initial statistical tests 
within each branch 
(BID, alpha=0.04 and QD, alpha=0.01) were added.
9.[ADDRESS_35342] ‚Äúimportant‚Äù changed to  ‚Äúrelevant‚Äù in per protocol set 
definitionUpdated terminology.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 7SUMMARY OF KEY CHANGES TO THE REVISED PROTOCOL
Section Number 
& TitleDescription of Change Brief Rationale
[IP_ADDRESS]
NonrespondersNonresponder imputation (NRI) section updatedUpdated to clarify that 
this NRI is applicable 
to the primary and 
secondary endpoints at Week 32 and Week 48. Further guidancefor other endpoints
/timepoints will be
provided in the SAP.
[IP_ADDRESS] Analysis 
MethodologySingle randomization stratum co mbining Region (US, Latin 
America, Rest of World, Japan [other stratification factors will  not 
be applied in Japan]), CS dose at baseline (‚â• 10 mg/day or < 10 
mg/day) and SLEDAI -2K at baseline (‚â• 10 or < 10) added for 
logistic regression, Cochran -Mantel-Haenszel and repeated 
measures analysis Clarification of how to 
handle the lack of CS 
and SLEDAI -2K 
stratification within 
Japanese subjects
9.3.[ADDRESS_35343] completed 48 weeks of double
-blind 
treatment (or have 
discontinued).
APPENDIX [ADDRESS_35344] 30 days prior to initiation of study therapyTo align with informed 
consent language 
across all BMS
-986165 studies
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 8STUDY ACKNOWLEDGMENT/DISCLOSURE
I understand that this protocol contains information that is co nfidential and proprietary to Bristol-Myers 
Squibb Company (BMS). Any supplemental information that may be a dded to this document is also 
confidential and proprietary to B MS and must be kept in confidence in the same manner as the contents of 
this protocol.
I have read the original protocol/revised protocol and agree th at it contains all necessary details for carrying 
out the study as described. I will conduct this protocol as out lined therein and will make a reasonable effort 
to complete the study within the time designated.I will provide copi[INVESTIGATOR_35778]. I will discuss this material with them to  ensure that they are fully informed about the 
investigational product and the study. I will provide protocol information to my Institutional Review Board(s) [IRB(s)] or Independent Ethics 
Committee(s) [IEC(s]. I understand that original protocol/revis ed protocols must be reviewed by [CONTACT_35829][INVESTIGATOR_35779].
I agree that the contents of the protocol may not be disclosed to any other person or entity or used for any 
other purpose without the prior written consent of BMS. The for egoing shall not apply to disclosure required 
by [CONTACT_1956]; however, I will give promp t notice to BMS of any such disclosure.
I agree that the study data derived from this protocol may only  be used and disclosed in furtherance of the 
protocol, for the medical treatment of a study subject or for p ublication of study results in accordance with 
the terms of the clinical trial agreement or as otherwise permi tted by [CONTACT_35830].
I agree not to collect or use samples (e.g., tissue, blood, ser um, urine) or collect data (other than for 
diagnostic or treatment purposes) from the study subjects while  enrolled in the study, except as expressly 
permitted by [CONTACT_35831].
I understand that I may terminate or suspend enrollment of the study at any time if it becomes necessary to 
protect the best interests of the study subjects. Unless otherw ise provided in the clinical trial agreement, the 
study may be terminated at any time by [CONTACT_20444], with or without cau se.
Original Protocol : Revised Protocol :
Protocol Number: IM011021 Site Number: 
Date of Protocol or Revised Protocol: 15-Apr-2020
IND Number: [ADDRESS_35345] Number: 2017-001203-79
Investigator: Date: 
(signature)
(printed name)
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 9TABLE OF CONTENTS
TITLE PAGE.................................................................................................................... ...............[ADDRESS_35346] OF FIGURES ................................................ ............................................................... ........13  
1 PROTOCOL SUMMARY..........................................................................................14  
1.1 Synopsis....................................................... ...............................................................14  
1.2 Schema........................................................................................................................17  
1.3 Schedules of Activities ...............................................................................................17  
2 INTRODUCTION ................................................... ...................................................29  
2.1 Study Rationale...........................................................................................................29  
2.2 Background.................................................................................................................30  
2.2.2  Early Clinical Experience...........................................................................................32  
2.3 Benefit/Risk Assessment ............................................................................................34  
3 OBJECTIVES AND ENDPOINTS....................................... .....................................35  
4 STUDY DESIGN .......................................................................................................38  
4.1 Overall Design ................................................. ...........................................................38  
4.1.1  Data Monitoring Committee and Other External Committees...................................40  
4.2 Number of Subjects ............................................. .......................................................40  
4.3 End of Study Definition..............................................................................................40  
4.4 Scientific Rationale for Study Design .......................... ..............................................40  
5 STUDY POPULATION............................................... ..............................................42  
5.1 Inclusion Criteria ............................................. ...........................................................43  
5.2 Exclusion Criteria ............................................. ..........................................................46  
5.3 Randomization.................................................. ..........................................................50  
5.4 Lifestyle Restrictions ......................................... .........................................................50  
5.5 Screen Failures............................................................................................................50  
5.5.1  Retesting During Screening Period; Rescreening......................................................50  
6 TREATMENT ...................................................... ......................................................51  
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 106.1 Treatments Administered........................................ ....................................................53  
6.2 Method of Treatment Assignment ................................. .............................................53  
6.3 Blinding ......................................................................................................................53  
6.3.1  Maintaining the Blind.................................................................................................53  
6.4 Dosage Modification ............................................ ......................................................54  
6.5 Preparation/Handling/Storage/Accountability.................... ........................................55  
6.5.1  Retained Samples for Bioavailability/Bioequivalence................................................55  
6.6 Treatment Compliance................................................................................................55  
6.7 Concomitant Therapy .................................................................................................55  
6.7.1  Prohibited and/or Restricted Treatments ...................................................................[ADDRESS_35347] Result Abnormalities........................................................................66  
8.3.8  Potential Drug-Induced Liver Injury..........................................................................66  
8.3.9  Other Safety Considerations.......................................................................................66  
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 118.[ADDRESS_35348] X-ray ...................................................................67  
8.5.3  Clinical Safety Laboratory Assessments.....................................................................67  
8.5.4  Imaging Safety Assessment .........................................................................................68  
8.6 Pharmacokinetics............................................... .........................................................68  
8.6.1  Sampling Schedule......................................................................................................69  
8.6.2  Sampling Windows......................................................................................................69  
8.7 Supplemental Assessments: Photography .......................... ........................................70  
8.8 Pharmacogenomics ............................................... ......................................................70  
8.9 Biomarkers..................................................................................................................70  
8.9.1  Predictors of Response ...............................................................................................71  
8.9.2  Pharmacodynamics and Mechanism of Action...........................................................71  
9 STATISTICAL CONSIDERATIONS ..................................... ..................................72  
9.1 Sample Size Determination ........................................................................................72  
9.2 Populations for Analyses ............................................................................................73  
9.3 Statistical Analyses.....................................................................................................73  
9.3.1  Efficacy Analysis.........................................................................................................74  
[IP_ADDRESS]  Endpoints ....................................................................................................................74  
[IP_ADDRESS]  Nonresponders............................................................................................................75  
[IP_ADDRESS]  Analysis Methodology.................................................................................................75  
9.3.2  Safety Analyses ...........................................................................................................79  
9.3.3  Other Analyses............................................................................................................79  
[IP_ADDRESS]  Pharmacokinetics .......................................................................................................79  
[IP_ADDRESS]  Pharmacodynamics.....................................................................................................79  
9.3.4  Interim Analyses .........................................................................................................79  
9.3.5  Analysis and Reporting...............................................................................................79  
10 REFERENCES ..................................................... ......................................................80  
11 APPENDICES ............................................................................................................83  
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 12APPENDIX 1  STUDY GOVERNANCE CONSIDERATIONS ................................ ......84  
APPENDIX 2  ABBREVIATIONS AND TRADEMARKS .............................................91  
APPENDIX 3  ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING ..............................95
 
APPENDIX 4  WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND METHODS OF CONTRACEPTION ................................... ...........99
 
APPENDIX 5  SYSTEMIC LUPUS INTERNATIONAL COLLABORATINGCLINICS CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS............................................. ....................102
 
APPENDIX 6  COMMONLY USED CORTICOSTEROID EQUIVALENTS ..............104  
APPENDIX 7  REQUIRED RECOVERY (WASHOUT) TIMES FOR SPECIFIC MEDICATIONS PRIOR TO SCREENING ................................. ..........[ADDRESS_35349] RESULTS ........................................................ ........................................108
 
APPENDIX 10  BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX ‚Äì2004 ......110  
APPENDIX 11  SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX 2000 DISEASE ACTIV ITY QUESTIONNAIRE...................... 112
 
APPENDIX 12  CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA 
AND SEVERITY INDEX (CLASI)..................................... ...................114  
APPENDIX 17  OTHER ASSESSMENTS .......................................................................128  
APPENDIX 18  MORPHINE MILLIGRAM EQUIVALENTS FOR OPI[INVESTIGATOR_35780] ..............129  
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 13LIST OF TABLES
Table 1: Screening Procedural Outline (Protocol IM011021)...... .................................................18  
Table 2: Treatment Period Procedural Outline Up to Week 24 (Protocol IM011021)..................20  
Table 3: Treatment Period Procedural Outline After Week 24 (Pro tocol IM011021) ..................25  
Table 4: Objectives and Endpoints ............................................................................................. ...35  
Table 5: Study Treatments for IM011021 ......................... ............................................................52  
Table 6: Selection and Timing of Dose .......................... ...............................................................53  
Table 7: PK and PD Sampling S chedule for BMS-[ADDRESS_35350] OF FIGURES
Figure 1  Study Design Schematic ......................................... ...................................39  
Figure 2  Testing Strategy for SRI(4) Re sponse Rate, BID Branch.......... ................78  
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 141 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate 
Efficacy and Safety of BMS-986165 in Subjects with Systemic Lup us Erythematosus
Study Phase: 2
Rationale:
BMS-[ADDRESS_35351], potent, oral tyrosine kinase 2 (TYK2) inhibitor with a novel, highly 
selective mechanism of action th at has the potential to safely and effectively treat a broad spectrum 
of immune-mediated diseases. Tyrosine kinase 2 activates intrace llular signal transducer and 
activator of transcription (STAT)-dependent transcription and f unctional responses downstream 
of receptors for critical immune mediators, such as interleukin  (IL)-12, IL-23, and Type I and III
interferons (IFNs) .1,2,3These immune and inflammatory signaling pathways are critical i n the 
pathophysiology of various immune-mediated diseases including p soriasis, lupus, 
spondyloarthritis, inflammatory bowel disease (IBD), dermatomyo sitis, and Type I
interferonopathies .4,5BMS-986165 potently inhibits IL-23-, IL-12-, and Type I/III IFN -driven 
responses and has demonstrated proof of mechanism in mouse mode ls of autoimmunity (psoriasis, 
colitis, and systemic lupus erythematosus [SLE]) and in healthy  humans .5,[ADDRESS_35352] e reasons, as follows: 1) the 
major pathways in the TYK2 signaling cascade (Type I IFN and IL -12/23 and the downstream 
mediators IFNŒ≥ and IL -17) have been implicated in SLE disease pathogenesis ;72) biologic agents 
targeting the IL- 12/[ADDRESS_35353], or the IFNŒ± (or the Type I IFN) receptor have be en shown to be 
efficacious in Phase 2 studies of SLE8; and 3) the ability to measure circulating target-specific 
(such as suppression of IFN-stimulated gene expression) and dis ease-specific pharmacodynamic 
(PD) measures in SLE both before and after treatment allows for  establishing exposure-response 
relationships for PD endpoints in this condition.
The present study is the first study of this TYK2 inhibitor conducted in subjects with SLE and is 
intended to determine whether t he pharmacological effects of TY K2 inhibition are associated with 
objective clinical improvement in SLE disease activity and rela ted biomarkers. The study is also 
designed to assess the safety and tolerability of short- and lon g-term BMS-986165 treatment in 
subjects with SLE and to determine the dose level that provides  the optimal balance of efficacy 
and safety.
Study Population:
The study will enroll male and female subjects, 18 to 75 years o ld (inclusive), with SLE defined 
as follows:
xMeeting the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria 
for SLE9
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 15xBeing positive for one of the following: antinuclear antibody ( ANA) ‚â• 1:80 or positive anti-
double-stranded deoxyribonucleic aci d (dsDNA; indeterminate val ues are considered positive)
or positive anti-Smith (Sm) as de termined by [CONTACT_35832] 2000  (SLEDAI-2K) score
‚â•6 points and clinical SLEDAI-2K scor e ‚â•4 (points from organic brain syndrome, headache,
alopecia, and mucosal ulcers do not count towards the SLEDAI-2K  score for the purposes of
inclusion)
Those with drug-induced SLE, certain other immune-mediated dise ases, and active, severe lupus 
nephritis or central nervous system lupus will be excluded. To be randomized on Day [ADDRESS_35354] meet criteria  related to active musculoskeletal 
and/or mucocutaneous disease , with a clinical SLEDAI ‚â• 4.
Objectives and Endpoints:
Objective Endpoint
Primary Efficacy
xTo assess the effect of BMS-986165 on
SLE Responder Index (SRI)(4) response at
Week 32 in subjects with SLExProportion of subjects who meet response
criteria for SRI(4) at Week 32 ( Section 8.1)
Secondary Efficacy
xTo assess the effect of BMS-986165 on
measures of global and organ- specific
clinical responsesxProportion of subjects who meet response
criteria for SRI(4) at Week 48
xProportion of subjects who achieve a
British Isles Lupus Assessment Group
(BILAG)-based Composite Lupus
Assessment (BICLA) response at Week 48
xProportion of subjects who achieve Lupus
Low Disease Activity State (LLDAS )a t
Week 48
xProportion of subjects with a Cutaneous
Lupus Erythematosus Disease Area and
Severity Index (CLASI) activity score ‚â• 10
at baseline who achieve a CLASI response,
defined as a decrease of ‚â• 50% from
baseline CLASI act ivity score at Week 48
xChange from baseline in the 40- joint count
for tender, swollen, and tender + swollen
joints at Week 48
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 16Objective Endpoint
Safety
xTo assess the safety and tolerability of 
BMS-986165xNumber and proportion of subjects 
experiencing serious adverse events (SAEs); adverse events (AEs); and abnormalities in laboratory testing, vital 
signs, and electrocardiograms (ECGs)
Overall Design:
This is a randomized, placebo-controlled, double-blind, multice nter study to evaluate the efficacy 
and safety of BMS-986165 in subjects with SLE. The study includ es a screening period (SP) of 
up to 4 weeks (28 days); a 48-week (336-day) blinded treatment pe riod (TP); and a 28-day 
follow-up period (FP), for subjects who do not continue into the long-term extension (LTE) study 
(IM011074). The total duration will be approximately 56 weeks (3 92 days). Other details of 
study design are as follows:
xRandomization will be performed a fter completion of the SP, on Day 1 of the TP.
xRandomization in a 1:1:1:1 ratio will be performed using intera ctive response technology 
(IRT) and will be stratified by [CONTACT_35833] (CS) dose (‚â• 10 mg/day or 
< 10 mg/day), screening SLEDAI- 2K score (‚â• 10 or < 10), and geographic region.
xThe blind will be maintained during the TP by [CONTACT_35834] (placebo and 3 mg
BMS-986165) provided in blister cards that are identical in app earance while providing the 
appropriate randomized dose.
xClinical, laboratory, and photographic evidence of disease activity will be reviewed by [CONTACT_35835]. 
xSafety data will be reviewed by [CONTACT_1578].
xThe primary analysis of Week [ADDRESS_35355] completed 48 weeks of double- blind treatment (or discontin ued from the study).
Number of Subjects: 
Approximately 360 subjects will be randomized to receive oral tre atment with BMS-986165
12 mg once daily (QD), 6 mg twice daily (BID), 3 mg BID, or placebo B ID.
Treatment Arms and Duration:
Study treatment: Subjects in all treatment groups will take oral doses of the in vestigational
product (IP) for 48 weeks during the TP as follows: BMS-986165 12 mg QD, 6 mg BID, 3 mg
BID, or placebo BID.
Approved 1.0 v
Approved
1.0
v
&OLQLFDO3URWRFRO ,0
%06 7<.,QKLELWRU
$SU5HYLVHG3URWRFRO)LQDO$SSURYHG
%06&RQILGHQWLDO 6WXG\7UHDWPHQWIRU,0
0HGLFDWLRQ 3RWHQF\ ,31RQ,3
%06 PJ ,3
3ODFHER 1RWDSSOLFDEOH ,3
,3 LQYHVWLJDWLRQDOSURGXFW
x7KHWRWDOGXUDWLRQRIVWXG\SDUWLFLSDWLRQIRUHDFKVXEMHFWLVX SWRDSSUR[LPDWHO\
ZHHNV GD\VLQFOXGLQJXSWRDZHHNGD\63DZH HNGD\73
DQGDZHHN GD\)3 IRUVXEMHFWVZKRGRQRWFRQWLQXHLQWRWK H/7(VWXG\
,0
x,QDOOWUHDWPHQWJURXSVVXEMHFWVZLOOWDNHWKHLUUDQGRPO\DVVL JQHGWUHDWPHQWWZLFHGDLO\
DVRUDOFDSVXOHVLQDEOLQGHGPDQQHU
x1RWLWUDWLRQRUPRGLILFDWLRQRI,3GRVHVLVSHUPLWWHG
 6FKHPD
%,' WZLFHGDLO\&6 FRUWLFRVWHURLG32 SHURVE\PRXWK4' RQ FHGDLO\6/( V\VWHPLFOXSXVHU\WKHPDWRVXV
 6FKHGXOHVRI$FWLYLWLHV
6FKHGXOHVRISURFHGXUHVDUHGHVFULEHGLQ 7DEOHIRUVFUHHQLQJ 7DEOHIRUWKHILUVWKDOIRIWKH73
XSWR:HHNDQG 7DEOHIRUWKHVHFRQGKDOIRIWKH73DIWHU:HHN
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 18Table 1: Screening Procedural Outline (Protocol IM011021)
ProcedureScreening Visit 
From Day -28Notes
Eligibility Assessments
Informed Consent X A subject is considered enrolled only when a protocol-specific informed consent is signed.
Enroll subject X Obtain number from IRT; contact [CONTACT_35836] T to screen fail those not el igible.
Inclusion/exclusion criteria X Section 5
Medical history X Include any toxicities or allergy rela ted to previous treatment s.
SLICC criteria for SLE X APPENDIX 5
BILAG-2004 Index X APPENDIX 10
SLEDAI-2K X APPENDIX 11
Physician‚Äôs Global 
AssessmentX Assessment of disease activity using a 3-point scale
40-joint count X Counts for tender, swollen, and  tender + swollen joints ( Section 8.1 )
CLASI X APPENDIX 12 ; photography as needed.
Review concomitant 
medicationsX Restricted medications are detailed in  APPENDIX 7 . Medication restrictions at screening are in Section 6 .
Safety Assessments
Physical examination XGeneral, head, eyes, ears, nose,  throat, neck, cardiovascular, lungs, abdominal, extremities, neurologic, 
psychiatric, skin, musculoskeletal
Physical measurements X Height and weight
Vital signs XBody temperature, respi[INVESTIGATOR_697],  and blood pressure and hear t rate; blood pressure a nd heart rate should be 
measured seated after at least [ADDRESS_35356] and cervical cancer 
screeningXInvestigators are encouraged to ensure screening is up to date according to local guidelines (women only). 
Because most patients with SLE are young women, screening for c ervical and breast cancer prior to 
randomization is encouraged as per local guidelines due to the small inherent risk of increased malignancy 
with immunosuppressant agents, but this screening is at the inv estigator ‚Äôs discretion.
Laboratory Tests
Hematology, chemistry, 
urinalysis, and coagulationX Includes blood and urine samp les; collect after at least 10 hou rs of fasting.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 19Table 1: Screening Procedural Outline (Protocol IM011021)
ProcedureScreening Visit 
From Day -28Notes
Serology XIncludes hepatitis C antibody, h epatitis B surface  antigen, hep atitis B core antibody, HIV 1 and 2, 
(Section  5.2)
Tuberculosis screening X In accordance with standard tes ting (details are provided in Section 8.5.2 )
Pregnancy test (urine) X Women of childbearing potential only
Follicle-stimulating hormone X Postmenopausal women only, to confirm status ( APPENDIX 4 )
Thyroid stimulating hormone X Free thyroxine will be assessed only if thyroid-stimulating hor mone is abnormal.
Spot urine for 
protein:creatinine ratioX
Serum complement (C3, C4) X
Autoantibodies XANA, anti-Ro (SSA), anti-La (SSB) , anti-RNP, anti-dsDNA, anti-S m, antiphospholipid antibodies: 
anti-cardiolipin, lupus antic oagulant, beta-2 glycoprotein 1
Coomb‚Äôs test (direct) X
Blood sample for gene 
expression analysisX Required for study entry but no t used for prospective subject s tratification
Blood for inflammation 
markersX Serum and plasma
Photography XSubjects who consented to photog raphy will be photographed at r andomization for baseline photographs, 
including all views per the Photography Manual. Subjects with r ash and/or alopecia at screening who 
consented to photography will be photographed beginning at scree ning. See Photography Manual for details.
ANA = antinuclear antibodies; an ti-Sm = anti-Smith; BILAG = Bri tish Isles Lupus Assessment Group; CLASI = Cutaneous Lupus Eryt hematosus Disease Area and Severity 
Index; dsDNA = double-stranded deoxyribonucleic a cid; HIV = human immunodefici ency virus; IRT = interactive response technology; RNP = ribonucl eoprotein; SAE = serious 
adverse event; SLE = system ic lupus erythematosus; SLEDAI -2K = Systemic Lupus Erythematosus Disease Activity Index 2000;  SLICC = Systemic Lupus International 
Collaborating Clinics
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 20Table 2: Treatment Period Procedural Outline Up to Week 24 (Protocol IM011021)
ProcedureWeek 0
D1Week 2
D15
(¬±3 d)Week 4
D29
(¬±3 d)Week 8
D57
(¬±3 d)Week 12
D85
(¬±3 d)Week 16
D113
(¬±3 d)Week 20
D141
(¬±3 d)Week 24
D169
(¬±3 d)Notes
Eligibility/randomization 
criteriaXConfirm eligibility criteria and assess 
randomization criteria ( Section 5.3). All 
procedures to be completed before 
dosing unless otherwise specified
Safety Assessments
Complete PE XGeneral, head, eyes, ears, nose, throat, 
neck, cardiovascular, lungs, abdominal, 
extremities, neurolo gic, psychiatric, 
skin, musculoskeletal
Targeted PE XXX X X X XGeneral, eyes, throat, cardiovascular, 
lungs, abdominal, ext remities, skin, 
musculoskeletal, and  others as clinically 
indicated
Body weight XX X X X X X
Vital signs XXXX X X X X See note in  Table 1
Electrocardiogram XX X X See note in  Table 1
Concomitant medication use XXXX X X X X
Monitor for AEs and SAEs X XSAEs from the signing of informed 
consent; AEs from time of first dose of 
the IP
Laboratory Tests Predose (note in  Table 1 ;Section 8.5.3 )
Hematology, chemistry, 
urinalysis, coagulationXXXX X X X X
Fasting lipid panel XX Predose, after at least a [ADDRESS_35357]
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 21Table 2: Treatment Period Procedural Outline Up to Week 24 (Protocol IM011021)
ProcedureWeek 0
D1Week 2
D15
(¬±3 d)Week 4
D29
(¬±3 d)Week 8
D57
(¬±3 d)Week 12
D85
(¬±3 d)Week 16
D113
(¬±3 d)Week 20
D141
(¬±3 d)Week 24
D169
(¬±3 d)Notes
Pregnancy test (WOCBP only) XXXX X X X X APPENDIX 4
Spot urine for protein creatinine 
ratioXX X X X X X
Coomb‚Äôs Test (direct) XX X X X X X
hsCRP XX X
TBNK XX X
Serum Ig XX X X IgM, IgA, IgG, IgE
PK Assessments XXXX X XNote: Fasting is required for Day 1 and 
Day 85. See Section 8.6
Biomarker Assessments
Serum Complement XXXX X X X X C3, C4
Anti-dsDNA autoantibodies X X X X X X X
Blood RNA for IRG and 
steroid signature, and genome-wide expression XXXXXaXXXPD assessment of IRG, steroid 
signature, and genome -wide expression 
analysis; predose; ( Section 8.9). 
 
ollection is to be anytime within 
the window, regardless of dosing time 
on the day of collection.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 22Table 2: Treatment Period Procedural Outline Up to Week 24 (Protocol IM011021)
ProcedureWeek 0
D1Week 2
D15
(¬±3 d)Week 4
D29
(¬±3 d)Week 8
D57
(¬±3 d)Week 12
D85
(¬±3 d)Week 16
D113
(¬±3 d)Week 20
D141
(¬±3 d)Week 24
D169
(¬±3 d)Notes
Efficacy AssessmentsNSAIDs must be withheld for 
‚â•12 hours before visits.
BILAG-2004 Index X X X X X X X
SLEDAI-2K X X X X X X X
Physician‚Äôs Global Assessment XX X X X X XAssessment of disease  activity using a 
3-point scale (0 to 3)
40-joint count X X X X X X X See note in  Table 1 .
CLASI X X X X X X X APPENDIX 12
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 23Table 2: Treatment Period Procedural Outline Up to Week 24 (Protocol IM011021)
ProcedureWeek 0
D1Week 2
D15
(¬±3 d)Week 4
D29
(¬±3 d)Week 8
D57
(¬±3 d)Week 12
D85
(¬±3 d)Week 16
D113
(¬±3 d)Week 20
D141
(¬±3 d)Week 24
D169
(¬±3 d)Notes
Photography XX X X X X XSubjects who consented to photography 
will be photographed at randomization for baseline photographs, including all views per the Photography Manual. 
Subjects with rash and/or alopecia at 
screening who consented to 
photography will be photographed 
beginning at screening. See Photography Manual for details.
Assess suitability for CS taper (X) (X) (X) XX X XTaper is not required to start until 
Week 8. The CS dose must remain 
stable from Week 20 to 32.
Patient‚Äôs Global Assessment XX X X X X XAssessment of disease  activity using a 
visual analog scale (APPENDIX 17 )
Pain assessment XX X X X X XUsing a numerical rating scale 
(APPENDIX 17 )
Clinical Drug Supplies
Randomization X Using IRT
Dispense Study Treatment X XStudy treatment dispensed on Day 169 
for the continued TP (Table 3 )
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 24Table 2: Treatment Period Procedural Outline Up to Week 24 (Protocol IM011021)
ProcedureWeek 0
D1Week 2
D15
(¬±3 d)Week 4
D29
(¬±3 d)Week 8
D57
(¬±3 d)Week 12
D85
(¬±3 d)Week 16
D113
(¬±3 d)Week 20
D141
(¬±3 d)Week 24
D169
(¬±3 d)Notes
Study Treatment 
AdministrationX X
Study Treatment Compliance XXX X X X X
AE = adverse event; ANA = antinuc lear antibodies; anti-Sm = ant i-Smith; BILAG = British Isles Lupus Assessment Group; CLASI = Cutaneous Lupus Erythematosus Disease Area and 
Severity Index; CS = corticosteroid; dsDNA = double-stranded de oxyribonucleic acid;  hsCRP = high-sensitivity C-reactive protein; 
Ig = immunoglobulin; IP = investigational product; IRG = interfer on-regulated genes; IRT=interactive response technology;  
NSAID = nonsteroidal anti-inflammatory drug; PD = pharmacodynami c(s); PE = physical examination; PK = pharmacokinetic(s);  
 RNA = ribo nucleic acid; RNP = ribonucleoprotein; SAE = serious adverse event;  SLEDAI-2K = Systemic Lupus 
Erythematosus Disease Activity Index 2000; SLICC = Systemic Lup us International Collaborating Clinics; TBNK = T cells, B cells, and natural killer cells; TP = treatment period; 
WOCBP = women of childbearing potential
aIntensive PD sampling on Day 85 is further described in Table 7 .
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 25Table 3: Treatment Period Procedural O utline After Week 24 (Protocol IM011021)
ProcedureWeek 28
D197
(¬±3 d)Week 32
D225
(¬±3 d)Week 36
D253
(¬±3 d)Week 40
D281
(¬±3 d)Week 44
D309
(¬±3 d)Week 48
D337/EOT
(¬±3 d)FP
(28 days 
after EOT)aNotes
Safety Assessments
Complete PE XXGeneral, head, eyes, ears, nose, 
throat, neck, cardiovascular, 
lungs, abdominal, extremities, 
neurologic, psychiatric, skin, 
musculoskeletal
Targeted PE XX X X XGeneral, eyes, throat, 
cardiovascular, lungs, abdominal, 
extremities, skin, musculoskeletal, and others as clinically indicated
Body weight X X X X X X X
Vital signs XXXXX X X See note in Table [ADDRESS_35358] (WOCBP only) X X X X X X X See note in  Table 1 .
Spot urine for protein creatinine 
ratioXXXXX X X
Coomb‚Äôs Test (direct) XXXXX X X
hsCRP XX X
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 26Table 3: Treatment Period Procedural O utline After Week 24 (Protocol IM011021)
ProcedureWeek 28
D197
(¬±3 d)Week 32
D225
(¬±3 d)Week 36
D253
(¬±3 d)Week 40
D281
(¬±3 d)Week 44
D309
(¬±3 d)Week 48
D337/EOT
(¬±3 d)FP
(28 days 
after EOT)aNotes
TBNK XX
Serum Ig XX X IgM, IgA, IgG, IgE
PK Assessments XX See Section 8.6
Biomarker Assessments
Serum Complement XXXXX X X C3, C4
Anti-dsDNA autoantibodies X X X X X X X
Blood RNA for IRG, steroid 
signature, and genome -wide 
expressionXXXXX X XAssessment of IRG, steroid 
signature, and genome -wide 
expression; predose ( Section 8.9 )
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 27Table 3: Treatment Period Procedural O utline After Week 24 (Protocol IM011021)
ProcedureWeek 28
D197
(¬±3 d)Week 32
D225
(¬±3 d)Week 36
D253
(¬±3 d)Week 40
D281
(¬±3 d)Week 44
D309
(¬±3 d)Week 48
D337/EOT
(¬±3 d)FP
(28 days 
after EOT)aNotes
Efficacy AssessmentsNSAIDs must be withheld for 
‚â•12 hours before visits.
BILAG -2004 Index X X X X X X X
SLEDAI -2K X X X X X X X
Physician‚Äôs Global Assessment XXXXX X XAssessment of disease activity 
using a 3 -point scale (0 to 3)
40-joint count X X X X X X X See note in Table 1 .
CLASI XXXXX X X APPENDIX 12
Photography XXXXX X XSubjects who consented to 
photography will be photographed 
at randomization for baseline 
photographs, including all views 
per the Photography Manual. Subjects with rash and/or alopecia at screening who consented to photography will be photographed 
beginning at screening. See Photography Manual for details.
Assess suitability for CS taper XXX XCS dose must remain stable 
Weeks 20 ‚Äì32 and 40 ‚Äì48.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 28Table 3: Treatment Period Procedural O utline After Week 24 (Protocol IM011021)
ProcedureWeek 28
D197
(¬±3 d)Week 32
D225
(¬±3 d)Week 36
D253
(¬±3 d)Week 40
D281
(¬±3 d)Week 44
D309
(¬±3 d)Week 48
D337/EOT
(¬±3 d)FP
(28 days 
after EOT)aNotes
Patient‚Äôs Global Assessment XXXXX X XAssessment of disease activity 
using a visual analog scale (APPENDIX 17
)
Pain assessment XXXXX X XUsing a numerical rating scale 
(APPENDIX 17 )
Clinical Drug Supplies
Dispense Study Treatment XXXXX
Study Treatment Administration XXXXX X
Study Treatment Compliance XXXXX X
ACR = American College of Rheumat ology; AE = adverse event; ANA  = antinuclear antibodies; anti-S m = anti-Smith; BILAG = Britis h Isles Lupus Assessment Group; 
CLASI = Cutaneous Lupus Erythematos us Disease Area and Severity I ndex; CS = corticosteroid; dsDNA = double-stranded deoxyribonuc leic acid; EOT = End of Treatment; 
FP = follow-up period; hsCRP = high-sensitivity C-reactive protei n; Ig = immunoglobulin; IRG = interferon-regulated gene;  
NSAID = nonsteroidal anti-inflammato ry drug; PD = pharmacodynamic( s); PE = physical examination; PK = pharmacokinetic(s);  
 RNA = ribonucleic acid; RNP = r ibonucleoprotein; SAE = serious adverse event;  
SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 2 000; SLICC = Systemic Lupus International Collaborating Clinics ; TBNK = T cells, B cells, and natural 
killer cells; WOCBP = women of childbearing potential
aOnly for subjects not continuing in the long-term extension stu dy IM011074
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 292 INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic progressive immune-mediated disease 
characterized by [CONTACT_35837]/tissue involvement and clini cal manifestations that are varied 
and widespread. The most commonl y affected body systems are muc ocutaneous, musculoskeletal, 
and renal. Progression of the dis ease is marked by [CONTACT_35838], and 
uncontrolled SLE leads to end organ damage and death. SLE preva lence in the [LOCATION_002] is 
estimated at 20 to 150 cases per 100,000, and incidence is esti mated at 1 to 25 per 100,000. Women 
are more frequently affected than men (9:1), as are people of A frican American and African 
Caribbean descent, and peak incidence occurs around the third o r fourth decade of life. 
Autoantibodies that define the autoimmune nature of SLE have be en identified. However, these 
autoantibodies are not specific to SLE. This and the variable c linical manifestations of SLE 
contribute to the complexity of diagnosis and treatment.
Current therapi[INVESTIGATOR_35781], and include immunosuppres sive drugs and corticosteroids 
(CS), which can temporarily control SLE flares and disease prog ression. However, the utility of 
these therapi[INVESTIGATOR_35782], and their use is associated wi th substantial undesirable effects 
that may outweigh any short-term improvements. One goal in the management of SLE is to achieve 
disease and symptom control while minimizing CS exposure. Treat ments include antimalarials, 
immunosuppressants, biologics including belimumab, and other ag ents (prescribed off-label). 
There remains an unmet need for novel, well-tolerated, orally a dministered therapi[INVESTIGATOR_35783].
2.1 Study Rationale
BMS-986165 is a potent, highly selective small molecule inhibit or of tyrosine kinase 2 (TYK2), 
which functions as a critical mediator in signaling pathways that regulate diverse, yet specific, 
immunomodulatory cellular responses, such as immunity, inflamma tion, and anti-inflammatory 
responses. BMS-[ADDRESS_35359] spectrum of 
immune-mediated diseases. Tyrosin e kinase 2 activates signal tr ansducer and activator of 
transcription (STAT)-dependent  transcription and functional responses downstream of critical 
immune mediators, such as interl eukin (IL)-12, IL-23, and Type I and III interferons (IFNs). 
BMS-986165 inhibits TYK2 through a novel allosteric mechanism, binding to the unique Janus 
kinase (JAK) homology 2 (JH2) domain, rather than binding direc tly to the active site .
1,2,3TYK2 
mediates immune and inflammatory signaling pathways critical in the pathophysiology of various immune-mediated diseases including psoriasis, lupus, spondyloar thritis, inflammatory bowel 
disease (IBD), dermatomyositis, and Type I interferonopathies .
4,5BMS-986165 potently inhibits 
IL-23-, IL-12-, and Type I/III IFN-driven responses and has dem onstrated proof of mechanism in 
mouse models of psoriasis, colitis, and lupus; and in healthy h uman volunteers .5,6
The proposed Phase 2 study in subjects with SLE will provide ev idence of biologic activity of 
BMS-986165 in a relevant diseas e population and will facilitate  dose ranging for future studies in 
SLE and other immune-mediated conditions. SLE is an ideal condi tion to evaluate the efficacy of 
the TYK2 inhibitor BMS-986165 for multiple reasons, as follows:  1) The major pathways in the 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 30TYK2 signaling cascade (Type I IFN and IL- 12/23 and the downstream mediators IFNŒ≥ and IL -17) 
have been implicated in SLE disease pathogenesis,72) Biologic agents targeting the IL-12/[ADDRESS_35360], or the IFNŒ± (or the Type I IFN) receptor are under investigation and have been shown to 
be efficacious in the treatment of SLE based on some Phase [ADDRESS_35361] been released. Thus, 
it is feasible that SLE patients treated with BMS-986165 may de rive therapeutic benefit, 3) It is 
also conceivable that TYK2 inhibition may show improved benefits  over existing anti-IFN 
monoclonal antibody therapi[INVESTIGATOR_35784]-12/23 and 
Type I IFN pathways,84) The ability to measure circulating target-specific (such as suppression 
of IFN-stimulated gene expression) and disease-specific pharmac odynamic (PD) measures in SLE 
both before and after treatment allows for establishing exposur e-response relationships for PD 
endpoints.
The present study is the first study of this TYK2 inhibitor conducted in subjects with SLE and is 
intended to determine whether t he pharmacological effects of TY K2 inhibition are associated with 
objective clinical improvement in SLE disease activity and rela ted biomarkers. The study is also 
designed to assess the safety and tolerability of short- and lon g-term BMS-986165 treatment in 
subjects with SLE, and to determine the dose level that provide s the optimal balance of efficacy 
and safety.
Research statement: The proportion of subjects with SLE who meet the response crite ria for the 
SLE Responder Index (SRI[4]) at Week [ADDRESS_35362] 1 of the BMS-986165
regimens than with placebo.
2.2 Background
Tyrosine kinase 2 (a member of the JAK family) catalyzes the pho sphorylation of STAT proteins 
downstream of the receptors for the p40-containing cytokines IL-[ADDRESS_35363]-in-class or ally administered small molecule 
inhibitor of TYK2 that has been shown to be superior to blockad e of the Type I IFN receptor in an 
IFN-dependent mouse model of SLE.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 31
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 322.2.2
Early Clinical Experience
The clinical data available to date supporting the safety, pharmacokinetics (PK), and PD of 
BMS-986165 are from 5 Phase 1 studies of BMS-986165 in healthy volunteers (IM011002, 
IM011015, IM011016, IM011031, and IM011039) and a Phase 2 study in adult subjects with moderate-to-severe psoriasis (IM011011).
Study IM011002 (Single and Multiple  Ascending Dose Study to Eva luate the Safety, Tolerability, 
PK, and PD of BMS-986165 in Healthy Subjects) used 1, 3, 10, 20 , and 40 mg doses for the 
single-dose part and 2, 4, 6, or 12 mg BID or 12 mg once daily (Q D) for 14 days for the multiple 
ascending dose part. All reported adverse events (AEs) were mild or moderate in severity, and 
approximately half of subjects overall had at least [ADDRESS_35364] infection. Dose-limiting AEs in the form of skin rashes and 
acneiform lesions were observed. These observations were largely reported for subjects in the 
24 mg/day (12 mg BID) group and were reported for most subjects dosed at this level. These events 
had not been observed earlier in the monkey studies. These AEs were mild or moderate in nature 
and resolved with topi[INVESTIGATOR_12969] (corticosteroid applicatio ns, benzoyl peroxide cream, 
clindamycin solution, chlorhexidine ointment). All events requi ring treatment responded 
appropriately and rarely resulted in discontinuation of study d rug. Overall, BMS-[ADDRESS_35365] 
doses were manageable with topi[INVESTIGATOR_12969], were reversible,  and were not serious or severe.
Study IM011016 (Pharmacokinetics and Metabolism of [
14C] BMS-986165 in Healthy Male 
Participants) used a single dose of 24 mg [14C] BMS- 986165 containing approximately 100 ŒºCi 
of total radioactivity. Five of the 6 enrolled subjects reporte d mild diarrhea (loose stools), and 1 of 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 33the 5 also had mild palpi[INVESTIGATOR_35785]. No deaths or discontinuations due to AEs 
were reported. 
Study IM011015 (The Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin) used a 
[ADDRESS_35366] on exposure to rosuvastatin. Fifteen o f 17 subjects who completed 
the study experienced an AE of acn e, and all these AEs were mil d or moderate in severity. Subjects 
with no or mild acne at baseline developed either mild or moder ate acne, whereas subjects with 
moderate acne at baseline generally experienced less worsening of their acne as the study 
progressed. In 2 subjects, an AE of moderate acne led to discon tinuation of study medication. All 
events of acne that required treatment responded to topi[INVESTIGATOR_35786]. 
In Study IM011039 (The Effect of BMS-986165 on the Pharmacokine tics of a Combined Oral 
Contraceptive), healthy subjects received 24 mg/day (12 mg BID) . Acneiform lesions (eg, skin 
rashes or pustules) were seen in all subjects at this dose and the number of events was similar to 
that in Study IM011002. According to the investigator, subjects  typi[INVESTIGATOR_35787] [ADDRESS_35367] dose of BMS-986165, fol lowed by [CONTACT_35839]/hairline-scalp, neck, and back on Day [ADDRESS_35368] dose, and all events 
resolved. All reactions were again mild or moderate and were managed with topi[INVESTIGATOR_12969].
Study IM011011 is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel 
group study to evaluate the clinical efficacy, safety, and PD of  BMS-986165 after 12 weeks of 
treatment with 4 weeks‚Äô follow -up in 267 subjects with moderate-to-severe psoriasis. The stud y 
met its primary and secondary efficacy endpoints of clinically relevant improvement in Psoriasis 
Activity and Severity Index and static Physician Global Assessme nt scores for 4 of the 5 doses 
investigated (only the 3 mg every other day dose did not meet t he primary endpoint). The most 
common AEs reported overall were nasopharyngitis, upper respi[INVESTIGATOR_1092], diarrhea, 
and nausea. The majority of the AEs reported in the study were m ild or moderate in intensity. The 
acneiform dermatitis AEs appeared  to be dose related, and most were reported for subjects in the 
[ADDRESS_35369] of the lesions were completely resol ved (a few were almost 
completely resolved) with topi[INVESTIGATOR_35788]. Several of the verbatim reported terms for the acnei form dermatitis group were similar 
to those previously reported for healthy subjects in Studies IM011002, IM011015, IM011031, and 
IM011039: ‚Äúacne on face neck and back,‚Äù ‚Äúpustular eruptions in face, neck and back‚Äù (sometimes 
including arms), or ‚Äúfolliculitis;‚Äù the similarity of these ter ms and a clear dose dependency suggest 
a common etiopathogenesis. 
In summary, BMS-[ADDRESS_35370] been  mild or moderate, nonserious, 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 34reversible, and have rarely led to discontinuation of study tre atment. There have been no signs or 
symptoms of circulatory or respi[INVESTIGATOR_35789] a systemic 
hypersensitivity reaction. The acneiform skin reactions requiring treatment have been well 
managed with topi[INVESTIGATOR_35790], clindamycin solution, 
chlorhexidine ointment, salicylic acid ointment, or retinoid ge l. The likely mechanism(s) behind 
the acneiform dermatitis is not currently known. 
In assessments of PK in Study IM011002, BMS-986165 achieved maximum plasma 
concentrations (Cmax) approximately 1 to 2 hours after dosing an d had a median terminal half-life 
ranging from 8 to 15 hours across the dose range tested. With si ngle dosing, BMS-986165
exposures appeared to increase in a greater than dose-proportional manner at doses less than 3 mg,
and in an approximately dose-depe ndent manner from 3 to 40 mg. After multiple-day dosing, 
BMS-986165 accumulation in the 1.4√ó to 1.9√ó range was observed at steady state. BMS-986165
is metabolized by [CONTACT_35840], but it does not inhibit cytochrome P450 (CYP450) 
enzymes at expected plasma concentrations. When taken with a high-fat meal, BMS-986165exhibited a lower Cmax and a dela yed time to maximum plasma con centration (Tmax) relative to 
dosing in the fasted state. Although the area under the concent ration-time curve extrapolated to 
infinity (AUC[0-INF]) was decreased by 15% in the fed state rel ative to the fasted state, this 
difference was not thought to be clinically meaningful.
A detailed description of the chemistry, pharmacology, efficacy, and safety of BMS-986165 is 
provided in the Investigator Brochure (IB).
2.3 Benefit/Risk Assessment
At this early stage in the development of BMS-[ADDRESS_35371]-in-human (FIH) st udy and within exposure margins 
based on comparisons of system ic exposure and body surface area .
The effects of TYK2 inhibition by [CONTACT_20444]-[ADDRESS_35372] been documented in pharmacology studies, 
and the potential for benefit in SLE has been suggested by [CONTACT_35841] a mouse model 
of SLE; further support is found in mouse models of other immun e-mediated diseases. Findings in 
toxicology studies were consistent with expectations based on t he pharmacology of BMS-986165.
Thus, the FIH study was conducted with standard safeguards within a range of dose regimens. Even at the highest exposures in healthy subjects, AEs were mild to moderate, reversible, and 
consistent with expectations  based on nonclinical experience.
The risk for PK drug-drug interactions (DDIs) with BMS-986165 was assessed based on regulatory guidelines. At the maximum concentrations expected in this stud y (in portal vein or systemic 
circulation, as appropriate), the potential for DDIs involving most transporters is low. 
BMS-[ADDRESS_35373] cancer res istance protein (BCRP) inhibitor with an in vitro 50% inhibitory 
concentration of 0.[ADDRESS_35374] of BMS-986165  on rosuvastatin PK showed less 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 35than 10% increase in exposures of rosuvastatin. Because of pote ntial PK interactions with the 
transporter P-glycoprotein (P-gp) as substrate, concomitant use  of strong inhibitors of P-gp is 
prohibited throughout the study. Treatment with BMS-986165 is n ot expected to diminish the 
effectiveness of contraceptives.
Nonclinical data and clinical experience in healthy subjects in  combination with the design and 
doses selected for the current Phase 2 study indicate an overall favorable risk/benefit assessment 
for investigating BMS-986165 as an oral treatment of patients w ith SLE. Detailed information 
about the known and expected benefits and risks and reasonably anticipated AEs of BMS-986165
is provided in the IB.
3 OBJECTIVES AND ENDPOINTS
Table 4: Objectives and Endpoints
Objectives Endpoints
Primary Efficacy
xTo assess the effect of BMS-986165 on the 
SRI(4) response at Week 32 in subjects with SLExProportion of subjects who meet response 
criteria for SRI(4) ( Section 8.1 ) at Week [ADDRESS_35375] of BMS-986165 on 
measures of global and organ- specific SLE 
clinical responsexProportion of subjects who meet response 
criteria for SRI(4) at Week 48
xProportion of subjects who achieve a British 
Isles Lupus Assessment Group-based 
Composite Lupus Assessment (BICLA) 
response at Week 48 after treatment with 
BMS-986165 or placebo administered on stable background therapy ( Section [IP_ADDRESS]
)
xProportion of subjects who achieve Lupus 
Low Disease Activity State (LLDAS) at 
Week 48 ( Section 8.1 )
xProportion of subjects with a Cutaneous 
Lupus Erythematosus Disease Area and 
Severity Index (CLASI) activity score ‚â• 10 at 
baseline who achieve a CLASI response, 
defined as a decrease of ‚â• 50% from baseline 
CLASI activity score at Week 48
(Section 8.1 )
xChange from baseline in the 40- joint count for 
tender, swollen, and tender + swollen joints at 
Week 48
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 36Table 4: Objectives and Endpoints
Objectives Endpoints
Safety
xTo assess the safety and tolerability of 
BMS-986165xNumber and proportion of subjects 
experiencing serious adverse events (SAEs); 
AEs; and abnormalities in laboratory testing, 
vital signs, and electrocardiograms (ECGs) throughout the study
Pharmacokinetics
xTo assess PK of BMS- 986165 and its active 
metabolite (BMT- 153261) in subjects with 
SLE ( Section 8.6 )xPlasma concentration of BMS- [ADDRESS_35376] of BMS- 986165 on PD 
markers ( Section 8.9.2 )xChange in mean and median interferon-
regulated gene (IRG) expression levels 
compared to baseline over time and at Week 32
x
Change in mean complement (C3, C4) and 
anti-double-stranded DNA (dsD NA) levels 
compared to baseline over time and at Week [ADDRESS_35377] of BMS-986165 on 
measures of global SLE clinical response in 
subjects based on IRG status (ie, high versus 
low IRG signature) at Week 32
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 37Table 4: Objectives and Endpoints
Objectives Endpoints
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 38Table 4: Objectives and Endpoints
Objectives Endpoints
4 S
TUDY DESIGN
4.1 Overall Design
This is a randomized, placebo- controlled, double-blind, multice nter study to evaluate the efficacy 
and safety of BMS-986165 in subjects with SLE. The primary stud y endpoint is the proportion of 
subjects who meet SRI(4) response (see Section 8.1 ) at Week 32 after treatment with BMS-986165 
or placebo administered on stable background therapy. This endp oint will be used to evaluate the 
research statement ( Section 2.1 ).
The duration of study participation is approximately 56 weeks (3 92 days), as follows:
xScreening period (SP): up to 4 weeks (28 days)
xTreatment period (TP): 48 wee ks (336 days) of blinded treatment
xFollow-up period (FP): 28 days
Note: The FP is only for subjects who do not continue into the long-term extension (LTE) study 
(IM011074)
The study design schematic is presented in Figure 1 .
Approved 1.0 v
Approved
1.0
v
&OLQLFDO3URWRFRO ,0
%06 7<.,QKLELWRU
$SU5HYLVHG3URWRFRO)LQDO$SSURYHG
%06&RQILGHQWLDO )LJXUH 6WXG\'HVLJQ6FKHPDWLF
%,' WZLFHGDLO\&6  FRUWLFRVWHURLG32  SHURVE\PRXWK4'  RQ FHGDLO\6/(  V\VWHPLFOXSXVHU\WKHPDWRVXV
2WKHUDVSHFWVRIVWXG\GHVLJQDUHDVIROORZV
x5DQGRPL]DWLRQZLOOEHSHUIRUPHGDIWHUFRPSOHWLRQRIWKH63RQ 'D\RIWKH73
x5DQGRPL]DWLRQLQDUDWLRZLOOEHSHUIRUPHGXVLQJLQWHUD FWLYHUHVSRQVH
WHFKQRORJ\,57DQGZLOOEHVWUDWLILHGE\VFUHHQLQJ&6GRVH¬ï  PJGD\RU
 PJGD\6/('$, .VFRUH¬ï RUDQGUHJLRQ8QLWHG6WDWHVRI$PHULFD
>86$@/DWLQ$PHULFDUHVWRIZRUOGDQG-DSDQ>RWKHUVWUDWLILF DWLRQIDFWRUVZLOOQRWEH
DSSOLHGLQ-DSDQ@
x7KHEOLQGZLOOEHPDLQWDLQHGGXULQJWKH WUHDWPHQWSHULRG 73E\W KHXVHRIPDWFKHG
FDSVXOHVSODFHERDQG  PJ%06SURYLGHGLQEOLVWHUFDUGV WKDWDUHLGHQWLFDO
LQDSSHDUDQFHZKLOHSURYLGLQJWKHDSSURSULDWHUDQGRPL]HGGRVH
x&OLQLFDOODERUDWRU\DQGSKRWRJUDSKLFHYLGHQFHRIGLVHDVHDFWL YLW\ZLOOEHUHYLHZHGE\
EOLQGHGH[WHUQDOUHYLHZHUV
x7KHSULPDU\HIILFDF\DQDO\VLVZLOOEHEDVHGRQ:HHN HIILFDF\ DVVHVVPHQWV
x&6WDSHULQJZLOOEHPDQDJHGDVGHVFULEHGLQ 6HFWLRQ  
x6XEMHFWVZLOOEHFRQVLGHUHGQRQUHVSRQGHUVIRUDQDO\VLVSXUSRVHV XQGHUFLUFXPVWDQFHV
DVGHVFULEHGLQ 6HFWLRQ  
Approved 1.0 v Approved 1.0 v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 40xAn independent data monitoring c ommittee (DMC) will assess safety and efficacy data.
xPhysical examinations, vital sign measurements, 12-lead electro cardiograms (ECGs),
and clinical laboratory evaluations  will be performed at select ed times throughout the 
dosing interval. Subjects will be closely monitored for AEs thr oughout the study. 
Blood samples will be collected f or PK and PD analyses as well.
xSamples for biomarker assessments will be collected from a subs et of subjects (those 
at [LOCATION_003] sites only) on Day 2 or 3 ([ADDRESS_35378] do se).
4.1.[ADDRESS_35379] (infections and skin re actions), focusing on early signal 
detection. Further details on the frequency, content, and metho ds of data reports to the DMC will 
be outlined in the DMC charter along with the processes and pro cedures the committee will follow.
Central Review Service s (CRS) will be used in this study. The s cope of responsibility will include  
 review of SLE eligibility criteri  
 
 
.
4.2 Number of Subjects
Approximately 360 subjects will be randomized 1:1:1:1 to receive BMS-986165 12 mg QD, 
6 mg BID, 3 mg BID, or placebo BID during the TP. Sample size considerations are described in 
Section 9.1.
4.3 End of Study Definition
The duration of study participation for individual subjects is expected to be approximately 
56 weeks (392 days). 
The start of the study is defined as first visit for first subj ect screened. The end of the study is 
defined as the last visit or sch eduled procedure shown in the S chedules of Activities ( Section 1.3)
for the last subject. Study completion is defined as the final date on which data for the primary 
endpoint was expected to be collected, if this is not the same.  The end of the study for analysis of 
biomarker samples is mentioned in Section 8.9 .
4.4 Scientific Rationale for Study Design
The primary purpose of the study is to determine the optimal do se of BMS-986165 for treatment 
of subjects with SLE. A placebo control is included to allow th e effects of treatment, both desired 
and adverse, to be appropriately attributed to treatments recei ved. All subjects will be permitted to 
continue their existing therap ies for SLE, and rescue treatment s are permitted as needed (with a 
few protocol-specified limitations) to allow subjects to mainta in standard disease control 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 41regardless of the effects of their assigned study treatment. A plan for CS tapering is included to 
allow subjects to use the lowest dose that meets their needs th roughout much of the study, but 
doses are held stable for 12 weeks before the Week 32 assessments  (primary efficacy) and for 
8 weeks before the Week 48 assessments to isolate effects of ass igned study treatments. A DMC 
will monitor safety and efficacy findings throughout the study to allow timely management of any 
concerns that arise. Study visits allow for close monitoring of  subjects. The eligibility and 
randomization criteria are designed to ensure that subjects hav e the expected level of SLE disease 
activity and to minimize the risk for serious infections that m ay be associated with 
immunosuppressive therapi[INVESTIGATOR_014]. Randomization is stratified by [CONTACT_35842]-2K score, and region in order to balance subjects equally across treatment groups based 
on these characteristics, which may indicate the background severity of disease and/or background 
level of disease control and will also balance for potential re gional differences in SLE background 
medication.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential [ADDRESS_35380]‚Äôs routine clinical management and obtained be fore signing of 
informed consent may be utilized for screening purposes, provid ed the procedure meets the 
protocol-defined criteria and has been performed within the tim eframe defined in the Schedules of 
Activities ( Section 1.3 ). However, all laboratory testing must be performed by [CONTACT_1758]-specific 
central laboratory.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 43The duration of the screening period (SP) is up to [ADDRESS_35381] meet all of the following 
criteria:
1) Signed Written Informed Consent
a) Willing to participate in the study and have the ability to g ive informed consent 
b) Willing and able to complete all study-specific procedures an d visits
2) SLE Disease Characteristics
a)Diagnosed ‚â• 24 weeks before the screening visit
b) Meets the Systemic Lupus International Collaborating Clinics (SLICC) classification 
criteria for SLE9APPENDIX 5
c)One of the following: elevated antinuclear antibodies (ANA) ‚â• 1:80 or positive 
anti-dsDNA (positive includes indeterminate results) or positiv e anti-Smith (anti-Sm) as 
determined by [CONTACT_2237]
d) Total SLEDAI- 2K score ‚â• 6 points and clinical SLEDAI- 2K score ‚â• 4 points with joint 
involvement and/or rash (score must be confirmed by [CONTACT_35843])
i) Lupus headache, alopecia, organic brain syndrome, and mucosal  ulcers cannot count 
toward the points required for screening at entry.
ii) Clinical SLEDAI-2K excludes laboratory abnormalities such as  hematuria, pyuria, 
urinary casts, proteinuria, positive anti-dsDNA, decreased comp lement, 
thrombocytopenia, and leukopenia.
e) At least 1 of the following BILAG-based protocol-specific man ifestations of SLE  
:
i) BILAG A or B grade in the Mucocutaneous body system.  
 
 
 
ii) Modified BILAG A or B score in the Musculoskeletal body syst em  
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 44 
 
 
 
 
 
 
iii)
If only [ADDRESS_35382] be present 
in one of the other body systems, for a total of 2 BILAG B body system grades.
3) Medications for SLE
a) Background therapy is required for ‚â•[ADDRESS_35383] be at
a stable dose for ‚â•8 weeks before the screening visit and remain stable until 
randomization and throughout study participation. Details for spec ific medications are as
follows:
xImmunosuppressants (combinations of these are NOT permitted):
oazathioprine (maximum 200 mg/day)
o6-mercaptopurine (6-MP)
omethotrexate (MTX; maximum 25 mg/week; dose and route of administration
of MTX may not be changed for 8 weeks before the screening visit andthroughout study participation)
oleflunomide
omycophenolate mofe til/myco phenolic acid (MMF). Note: Subjects who are
receiving MMF may participate in the study only if administered as amaintenance therapy and up to a maximum of 2 g/day (or equivalent); in subje cts
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 45of African ancestry, 3 g/day (or equivalent) is acceptable. Treatment may be
interrupted due to neutropenia per the product label.
xAntimalarials: chloroquine, hydroxychloroquine, or quinacrine; monot herapy is
permitted if the minimum doses are met: chloroquine 125 mg QD, 
hydroxychloroquine 200 mg QD, or quinacrine 100 mg QD
xRequired discontinuation periods for other immunomodulatory drugs (eg,
cyclosporine, tacrolimus, etc) or biologic drugs (eg, rituximab, belimu mab,
tocilizumab, etc) are provided in APPENDIX 7 .If a drug is not specifically listed, 
consult the  medical monitor for guidance. Usual discontinuat ion periods are 
4 weeks or 5 half-lives, whichever is longer.
b) CS (prednisone or equivalent) background therapy is permitted  but not required. For 
subjects taking CS, the dose must be stable for ‚â• 2 weeks before the screening visit, 
cannot exceed 30 mg/day at screening, and must remain stable unt il randomization. 
CS monotherapy is not permitted. Prednisone equivalents are provi ded in APPENDIX 6 .
c) Requirements for subjects who are receiving chronic therapy w ith nonsteroidal 
anti-inflammatory drugs (NSAIDs; including marketed cyclooxygena se-2 inhibitors) are 
as follows; exceptions or changes may be possible with approval  by [CONTACT_35844]:
xDoses must be stable for [ADDRESS_35384] remain stable 
until randomization and throughout the study.
xNo more than 1 oral NSAID may be used (at a stable dose) during  the study and 
may be combined with topi[INVESTIGATOR_35791].
xUse of [ADDRESS_35385] follow a stable regimen 
throughout the study.
xAspi[INVESTIGATOR_9022] (in addition to a single NSAID and topi[INVESTIGATOR_2855] N SAIDs) at stable 
doses no higher than 325 mg/day throughout the study.
4)Age and Reproductive Status
a) Men and women aged 18 to 75 years inclusive at the time of scr eening
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic 
gonadotropin [Œ≤ -HCG]) within 24 hours prior to the start of study treatment.
c) Women must not be breastfeeding.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 46d) WOCBP must agree to follow instructions for method(s) of cont raception for the duration 
of treatment with study treatment(s) (BMS-986165 or placebo) pl us 5 half-lives of study 
treatment (3 days) plus 30 days (duration of ovulatory cycle) for  a total of [ADDRESS_35386] 
treatment completion.
e) WOCBP who are continuously not h eterosexually active are exem pt from contraceptive 
requirements and still must unde rgo pregnancy testing as descri bed in this section.
f) Investigators shall counsel WOCBP and men who are sexually active with WOCBP on the 
importance of pregnancy prevention and the implications of an u nexpected pregnancy. 
Investigators shall advise on the use of highly effective or less than highly effective 
methods of contraception (APPENDIX 4 ).
g) Men who are sexually active with WOCBP must agree to follow i nstructions for method(s) 
of contraception (APPENDIX 4 )for the duration of treatment with study treatment 
(BMS-986165 or placebo). 
h) Azoospermic males are exempt from contraceptive requirements.  
i) N/A per Revised Global Protocol im011021-revprot04
5.2 Exclusion Criteria
An individual who meets any of the following criteria will be e xcluded from participation in this 
study:
1) Target Disease Exceptions
a) Drug-induced SLE
b) Subjects with other autoimmune diseases (eg, multiple sclerosi s, psoriasis, IBD, etc) are 
excluded. Subjects with type I autoimmune diabetes mellitus, th yroid autoimmune disease, 
Celiac disease, or secondary Sj√∂gren‚Äôs syndrome are not excluded.
c) Subjects with SLE overlap syndromes such as scleroderma and mi xed connective tissue 
disease are excluded. Subjects with an overlap syndrome of SLE with rheumatoid arthritis
are not excluded as long as they meet the criteria for the clas sification of SLE as outlined 
in the inclusion criteria ( Section 5.1 , Inclusion Criterion  2).
d) Subjects with antiphospholipid antibody syndrome on stable an ticoagulant therapy at an 
effective dose (eg, if on warfarin, an international normalized  ratio [INR] target 2 to 3 or 
as appropriate for the clinical situation) are allowed if this is not the sole or the predominant 
feature of their SLE. Subjects with a serious thrombotic event (eg, pulmonary embolism, 
stroke, deep vein thrombosis) or unexplained pregnancy loss wit hin [ADDRESS_35387] rophic antiphospholipid 
syndrome or saddle embolism are excluded. Subjects with a histor y of 3 or more 
unexplained consecutive pregnancy losses would also be excluded .
e) Subjects with active or unstable lupus neuropsychiatric manife stations, including but not 
limited to any condition defined by [CONTACT_35845] A criteria are exclude d, with the exception of 
subjects with mononeuritis mul tiplex and polyneuropathy, who are  allowed.
f) Subjects with active, severe lupus nephritis (World Health Or ganization Class III, IV) that 
requires or may require treatment with cytotoxic agents or high -dose CS are excluded.
Subjects with prior, controlled renal disease with serum creati nine ‚â§ 2√ó upper limit of 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 47normal (ULN) and either residual proteinuria up to 3 g/day or a urine protein/creatinine 
ratio (UPCR) of 3 mg/mg or 339 mg/mmol are allowed. Control of renal disease must be 
documented with at least [ADDRESS_35388] 6 months.
2) Other Medical Conditions and History
a) Women who are pregnant or breastfeeding
b)Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, 
hematologic, gastrointestinal,  endocrine, pulmonary, immunologi c, psychiatric) or local 
active infection/infectious illness that, as determined by [CONTACT_35846], will 
substantially increase the risk to the subject if he or she par ticipates in the study
c) Any major surgery within the last [ADDRESS_35389] dose of study treatment, or any 
surgery planned during the course of the study
d) Cancer or history of cancer or lymphoproliferative disease within the previous 5 years 
(other than adequately treated cutaneous basal cell or squamous  cell carcinoma with no 
evidence of recurrence)
e) Class III or IV congestive heart failure as defined by [CONTACT_35847] w York Heart Association
(NYHA) or any recent onset of heart failure resulting in NYHA C lass III/IV symptoms
f) Acute coronary syndrome (eg, myocardial infarction, unstable angina pectoris) and/or any 
history of significant cerebrovascular disease within 24 weeks b efore screening
g) Current or recent (within 3 months before randomization) gastr ointestinal disease, 
including gastrointestinal surgery, that could impact the absor ption of study treatment
h) Subject with non-SLE concomitant illness, as determined by [CONTACT_35848], who is 
likely to require additional systemic glucocorticosteroid thera py during the study (eg, 
asthma).
i) Significant blood loss (> 500 mL) or blood transfusion within 4 weeks before 
randomization
j) Inability to take medication orally
k) Inability to undergo venipuncture  and/or tolerate venous acce ss
l) Recent (within 6 months be fore randomization) drug or alcohol abuse as defined by [CONTACT_35849] ( APPENDIX 8)
m) Any other sound medical, psychiatric, and/or social reason as  determined by [CONTACT_35850]
3) Prior and Concomitant Therapy
a) Inability to comply with re strictions and prohibited treatmen ts (Section 6.7.1 ); inability to 
comply with discontinuation requirements listed in APPENDIX 7
b) Taking more than 1 immunosuppressantc) Prior exposure to TYK2 inhibitorsd) Prior exposure to anifrolumab, rontalizumab, ustekinumab, or interferon alpha kinoid 
(INFŒ± Kinoid)
e) Current administration of opi[INVESTIGATOR_35792]:
i)The prescribed dose has been stable for ‚â• 4 weeks before screening
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 48ii) The drug is not used on an as-needed basis
iii) The dose is expected to remai n stable through the study per iod
iv) In the opi[INVESTIGATOR_871], the subject‚Äôs use of opi[INVESTIGATOR_35793]-specific efficacy and safety assessments
v) The dose does not exceed the equivalent of 30 mg of morphine p er day (see
APPENDIX 18 for morphine milligram equivalents of commonly used opi[INVESTIGATOR_2438])
f) Other investigational agents must be discontinued at least 12  weeks or 5 half-lives before 
screening, whichever is longer
4) Findings Related to Possible Infection
a) Evidence of active or latent tuberculosis (TB), as follows:
xPositive chest X-ray for evidence of active pulmonary TB within [ADDRESS_35390] X-ray within 6 months before screen ing may be 
eligible provided any of the following apply:
onegative IFN gamma release assay (IGRA)
opositive IGRA and no symptoms of active TB, and have previously  
(within 5 years) received adequate documented treatment for late nt TB, 
per investigator‚Äôs medical judgment
opositive IGRA and no symptoms of active TB, but have NOT previo usly 
(within 5 years) received adequate documented treatment, per 
investigator‚Äôs medical judgment; subject must initiate prophyla ctic 
treatment per local guidelines and may rescreen after 1 month of  
treatment (if subject is enrolled, the prophylactic TB treatmen t must 
continue throughout the study)
oindeterminate IGRA at screening with no signs or symptoms of act ive 
TB must be retested for confirmation. If the second test is aga in 
indeterminate, the subject will be excluded from the study. If the retest 
is positive, the subject should be treated as having latent TB infection.
If the retest is negative, subject may be eligible, provided no other 
exclusion criteria for TB is met
b) Hepatitis C, hepatitis B, or human immunodeficiency virus (HI V) infection as 
demonstrated by a positive blood screen for hepatitis C antibod y (anti-HCV), hepatitis B 
surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), or HIV-[ADDRESS_35391] been vaccinated for hepatitis B (hepatitis B surface antibody 
[anti-HBs]-positive) are not excluded. Note that anti-HBs is no t requested ( APPENDIX 9 ).
Note: Subjects who are newly found to be HIV-positive should be direc ted to appropriate 
follow-up care.
c) Currently on any therapy for chronic infection (eg, pneumocystis, cytomegalovirus, herpes 
simplex, herpes zoster, invasive bacterial or fungal infections , or atypi[INVESTIGATOR_4017])
d) History of congenital or acquired immunodeficiency
e) Known active infection, or any major epi[INVESTIGATOR_35794] (intramuscular or IV) antimicrobial a gents (eg, antibiotics, 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 49antiviral, antifungal, or antiparasitic agents) within 30 days o f randomization, or 
completion of oral antimicrobial agents within 2 weeks of rando mization
f) Previous history of herpes zoster, herpes simplex, or influen za infection within 12 weeks 
before randomization or a history of disseminated/complicated h erpes zoster infection 
(multidermatomal involvement, ophthalmic zoster, central nervou s system involvement, or 
post-herpetic neuralgia)
g) Administration of a live vaccine within 90 days or an inactiva ted vaccine within 30 days 
before randomization. Heat-killed or otherwise inactivated or protein vaccines (eg, 
influenza and pneumococcal vaccines) may be received at any tim e on study. Furthermore, 
live vaccines should not be used during treatment or within the  [ADDRESS_35392] 
dose, and any other inactivated vaccines (eg, tetanus, etc) sho uld be used according to local 
guidelines during the TP.
5) Physical and Laboratory Test Findings
a) Clinically significant abnormalities on chest X-ray or ECG
b) Clinically significant abnormalities in laboratory tests including the following:
i) Serum alanine aminotransferase  (ALT) > 2√ó ULN, unless explicit ly related to SLE
ii) Serum aspartate aminotransferase (AST) > 2√ó ULN, unless expli citly related to SLE
iii) Serum total bili rubin > 1.5√ó ULN, unless explicitly  related to SLE or documented  
Gilbert's syndrome 
iv) Hemoglobin < 8 g/dL (80 g/L) or, if due to hemolytic anemia related to SLE, < 7 g/dL
(70 g/L)
v) Proteinuria > 3.0 g/day (3000 mg/day) or equivalent level of pro teinuria as assessed 
by [CONTACT_35851] (3 mg/mg or 339 mg/mmol)
vi) Estimated glomerular filtration rate < 30 mL/minvii) Absolute white blood cell count < 1.2√ó 10
3/ŒºL (1.2√ó 109/L)
viii)P latelet count < 50 √ó 103/ŒºL (50 √ó 109/L)
ix) Abnormal free thyroxine (T4) (if the thyroid-stimulating hor mone [TSH] is abnormal 
at screening, a free T4 will be assessed; subjects with abnorma l TSH and abnormal 
free T4 will be excluded but after discussion with the  medi cal monitor may be 
able to rescreen a minimum of 6 weeks after adjustment of thyroid hormone 
replacement therapy).
c) Any other significant laboratory or procedure abnormalities, as determined by [CONTACT_35850], that might pose unacceptable risk to the subject during the study
6) Allergies and Adverse Drug Reaction
a) History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
7) Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a subject. Strict conditions apply and BMS approval is requi red).
b) Subjects who are compulsorily detained for treatment of eithe r a psychiatric or physical 
(eg, infectious disease) illness
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 50c) Inability to comply with the study protocol
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
subjects and that the results of the study can be used. It is imperative that subjects fully meet all 
eligibility criteria.
5.[ADDRESS_35393] 
dose:
1. The subject continues to satisfy all eligibility criteria.
2. If the subject had rash at screening, the subject must have a total score of the erythema and 
scale components (excluding mucous membrane ulcerations and non scarring alopecia) of the 
CLASI disease activity score of ‚â• 3.
3. If the subject had moderate or severe arthritis at screening,  the inclusion criteria for 
BILAG-based protocol-specific manifestations of SLE in Section 5.1 , Inclusion Criterion 2)e) 
must continue to be met.
5.[ADDRESS_35394] for patients with SLE, as follows: use of broad spectr um sunscreen (minimum sun 
protection factor 15 and with inorganic ingredients [zinc oxide , titanium dioxide]), avoiding sun 
exposure, wearing sun-protective clothing, avoidance of alcohol -based emollients, avoidance of 
over-the-counter anti-acne medications and alcohol-based skin care products, and avoidance of 
perfumed soaps and detergents, and similar measures.
Study treatment may be taken without regard to meals. However, s ubjects are required to fast for 
a minimum of 10 hours before visits on which fasting lipid and fasting glucose samples will be 
drawn (at 2 of these visits [Days  1 and 85], fasting PK samples  will also be drawn).
5.5 Screen Failures
Screen failures are defined as subjects who consent to particip ate in the clinical study but are not 
subsequently randomized in the study for any reason. A minimal set of screen failure information 
is required to ensure transparent reporting of screen failure subjects, to meet the Consolidated 
Standards of Reporting Trials publishing requirements, and to r espond to queries from regulatory 
authorities. Minimal information includes date of consent, demo graphy, screen failure details, 
eligibility criteria, and any serious AEs.
5.5.1 Retesting During Screening Period; Rescreening
For laboratory parameters and/or assessments that initially do not meet eligibility requirements, a 
single retest within the 28-day SP is permitted in an effort to  find all possible well-qualified 
subjects. Consultation with the  medical monitor may be need ed to identify whether repeat 
testing of any particular parameter is clinically relevant.
The study permits the rescreening (after the end of the initial 4-week SP) of a subject who 
discontinues the study as a pretreatment failure (ie, the subje ct fails screening or randomization 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 51and has not been treated). The subject must be reconsented and will be assigned a new 
identification number, and a full screening visit must be performed again. Other than exceptional 
circumstances which must be reviewed and approved by [CONTACT_35852] l monitor, a subject can only 
be rescreened 1 time. Depending on the timing of rescreening, r epetition of some assessments may 
not be required. Duration of existing treatments and required d iscontinuation periods shall be 
considered relative to the given screening visit and/or randomi zation.
The most current result prior to randomization is the value by [CONTACT_35853], as it represents the subject‚Äôs most current clinical state.
6 TREATMENT
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, or 
medical device intended to be administered to a study subject a ccording to the study randomization 
or treatment allocation
Study treatment includes both investigational [medicinal] produ ct (IP/IMP) and noninvestigational 
[medicinal] product (non-IP/non-IMP) and can consist of BMS-986165 and placebo. Information 
about the pharmacology and previous  experience with BMS-986165 is provided in Section 2.2 .
An IP, also known as IMP in some regions, is defined as a pharm aceutical form of an active 
substance or placebo being tested or used as a reference in a c linical study, including products 
already with a marketing authorization but used or assembled (f ormulated or packaged) differently 
than the authorized form, or used for an unauthorized indicatio n, or when used to gain further 
information about the authorized form.
Other medications used as support or escape medication for prev entative, diagnostic, or 
therapeutic reasons, as components of the standard of care for a given diagnosis, may be 
considered as noninvestigational products. Table 5 shows the study treatments for 
Protocol IM011021.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 52Table 5: Study Treatments for IM011021
Product 
Description/Class and 
Dosage Form Potency IP/Non-IPBlinded/Open
-LabelPackaging/
AppearanceStorage Conditions 
(per label) Comments
BMS-986165 oral capsule (as the free 
base)IP Blinded Blister card containing 
64 active
(3 mg BMS 986165) 
and/or placebo capsules 
to equal required daily 
dosingStore at 2¬∞C to 8¬∞C (36¬∞F 
to 46¬∞F). Store in original 
container.
Placebo matching BMS-
[ADDRESS_35395] containing 
64 active
(3mg BMS- 986165) 
and/or placebo capsules 
to equal required daily 
dosingStore at 2¬∞C to 8¬∞C (36¬∞F 
to 46¬∞F). Store in original 
container.
Any of the following: 
AZA, 6- MP, MTX, 
leflunomide, MMF; 
chloroquine, 
hydroxychloro quine, 
quinacrineAs prescribed Non-IP Open -label As provided As indicated Subjects are to be receiving at least 1 of these 
at a stable dose for ‚â• 8weeks before the 
screening visit, throughout the screening 
period, and throughout the study. See 
Inclusion 3a (Section 5.1 ) for further 
information. Non -IP will not be provided by 
[CONTACT_1034].
CS: prednisone (or 
equivalent)‚â§30 mg/day
(or equivalent)Non-IP Open-label As provided As indicated CS is not required; if on CS, the dose must be 
stable for ‚â• 2weeks before the screening 
visit, and throughout the SP. A dose up to 
30mg/day prednisone or equivalent is 
permitted at the screening visit (see Inclusion 
3b in Section 5.1) and should be tapered 
according to the protocol guidelines during 
the treatment period. Information about CS 
tapering  is provided in 
Sections 6.7.3
6-MP = 6-mercaptopurine; AZA = azathioprine, CS = corticosteroi d; IMP = investigational medicinal product; IP = investigationa l product; MMF = mycophenolate 
mofetil/mycophenolic acid; MTX = methotrexate; SP = screening p eriod
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 536.[ADDRESS_35396] been taken, that dose should b e not be taken and the next 
scheduled dose should be taken at the usual time.
Table 6: Selection and Timing of Dose
Study Treatment Unit dose strength(s)/
Dosage level(s)Dosage formulation
Frequency of AdministrationRoute of 
Administration
12 mg QD 
BMS- 9861653 mg 4 active capsules QD in the morning; and 
4placebo capsules QD in the eveningOral
6 mg BID 
BMS- 9861653 mg 2 active and 2 placebo capsules; BID Oral
3 mg BID 
BMS- 9861653 mg 1 active and 3 placebo capsules; BID Oral
Placebo Not applicable 4 place bo capsules; BID Oral
BID = twice daily; QD = once daily
6.[ADDRESS_35397] number (including subject s not subsequently randomized or 
treated). This number will be unique  across all sites. Enrolled subjects, including those not dosed, 
will be assigned sequential subj ect numbers. The subject number  may not be used for any other 
subject. If a potential subject is rescreened, they will be given a new identification number.
CRS and the PRA medical monitor will confirm subject eligibilit y based on criteria in Section 5 .
Eligible subjects will be centrally randomized using IRT to rec eive oral treatment with 
BMS-986165 12 mg QD, 6 mg BID, 3 mg BID, or placebo BID according to a computer-generated 
block randomization scheme and in accordance with stratificatio n criteria. Randomization 
numbers will be assigned prior to dosing.
Before the study is initiated, each user (at investigative site s) will receive log-in information and 
directions on how to access the IRT. Study treatment will be di spensed at study visits as shown in 
Section 1.3 (Schedules of Activities) .
6.3 Blinding
6.3.1 Maintaining the Blind
Blinded treatment assignments will be managed using IRT. All capsules (BMS-986165 3 mg and 
placebo) are identical in appearance, and they will be supplied  in blister packs with each daily dose 
made up of the appropriate combination of active and/or placebo  capsules to provide the correct 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 54treatment (as shown in Table 6 ). Investigative site staff, Sponsor and designee personnel, the  
(Section 4.1.1 ), and subjects and their families will remain blinded to treatment assignments. 
Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual subject in which knowledge of the IP 
is critical to the subject‚Äôs management, the blind for that sub ject may be broken by [CONTACT_093]. 
The subje ct‚Äôs safety takes priority over any other considerations in determining if a treatment 
assignment should be unblinded.
Before breaking the blind of an individual subject‚Äôs treatment,  the investigator should determine 
that the unblinded information is neces sary, ie, that it will alter the subject‚Äôs immediate 
management. In many cases, particularly when the emergency is c learly not related to the IP, the 
problem may be properly managed by [CONTACT_35854]. It is 
highly desirable that the decisi on to unblind treatment assignment be discussed with the  
medical monitor, but the investigator always has ultimate autho rity for the decision to unblind. 
The principal investigator [INVESTIGATOR_35795].For information on how to unblind in an emergency, consult the IRT manual.
In case of an emergency, the investigator has unrestricted acce ss to randomization information via 
IRT and is capable of breaking the blind through the IRT system without prior approval from the 
Sponsor. After the unblinding, the investigator shall notify th e  medical monitor and/or study 
director. The method of unblinding for emergency purposes is de scribed in the IRT manual. 
Subject information and the reason for the blind being broken must be recorded on the appropriate 
study status page of the electronic case report form (eCRF). Af ter unblinding via IRT, the 
investigator shall notify the  medical monitor.In cases of accidental unblinding, contact [CONTACT_35855] e the blind. Any request to 
unblind a subject for nonemergency purposes must be discussed w ith the  medical monitor 
prior to unblinding.
Designated staff of Bristol-Myers Squibb Research & Development  (or designee) may be 
unblinded (obtain the randomizati on codes) prior to database lo ck to facilitate the bioanalytical 
analysis of pharmacokinetic samples. A bioanalytical scientist in the Bioanalytical Sciences 
department of Bristol-Myers Squibb Research & Development (or a  designee in the external 
central bioanalytical laboratory) will be unblinded to (may obt ain) the randomized treatment 
assignments in order to minimize bioanalytical analysis of samp les.
6.4 Dosage Modification
There is no provision for dose modification of study treatment.  Titration of CS and its use as rescue 
therapy are discussed in Section 6.7.3 . Modification of other background SLE therapi[INVESTIGATOR_35796]. Subjects should continue to take their 
assigned treatment even if they experience flares and/or are un able to taper their CS dose, unless 
any of the criteria in Section 7.1 are met.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 55If a subject interrupts treatment due to an AE, study treatment  can be restarted in consultation with 
the  medical monitor.
6.5 Preparation/Handling/Storage/Accountability
The IP should be stored in a secure area according to local reg ulations. It is the responsibility of 
the investigator to ensure that IP is only dispensed to study s ubjects. The IP must be dispensed 
only from official study sites by [CONTACT_35856] g to local regulations.
The study treatment is stored in accordance with the environmen tal conditions (temperature, light, 
and humidity) required by [CONTACT_20444]. If concerns regarding the qualit y or appearance of the study 
treatment arise, the study treatment should not be dispensed and BMS should be contact[CONTACT_35857].
Investigational product documentation (whether supplied by [CONTACT_20447]) must be maintained that 
includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration, and, as applicab le, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
Further guidance and information for final disposition of unused study treatment are provided in 
APPENDIX 1 .
6.5.1 Retained Samples for Bioavailability/Bioequivalence
Not applicable.
6.[ADDRESS_35398] drug accountability 
procedures (comparing the number of capsules returned to number  dispensed, considering the 
expected regimen and any reported missed doses). Drug accountab ility will be reviewed by [CONTACT_35858]. Site staff will discuss any 
discrepancies with the subject and remind the subject of the im portance of compliance with the 
assigned regimen. A real-time monitoring platform may be used.
6.[ADDRESS_35399] be recorded; medications with dose changes may record the overall dates with last dose used. 
All medications taken from within [ADDRESS_35400] dose of 
study treatment (inclusive) must be recorded on the eCRF. Other  than existing treatment for SLE 
(with restrictions as described in the eligibility criteria [ Section 5.1 ]), concomitant medications 
(prescription, over-the-counter [OTC], or herbal) should only be administered during the study if 
they are prescribed for treatment of specific clinical events.
6.7.1 Prohibited and/or Restricted Treatments
Restrictions and prohibitions on prior and concomitant medicati ons are as follows:
1. Prior exposure to BMS-986165 or other TYK2 inhibitors is proh ibited.
2. Rescue therapy other than pre dnisone or equivalent is prohibi ted.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 563. Use of intramuscular, intra-articular, intrabursal, and IV CS is prohibited (Inclusion
Criterion 3)b); Section 5.1 ). Initiation during the study of short-term treatment with inh aled
CS for a nonlupus medical condition must be discussed with the  medical monitor. Topi[INVESTIGATOR_35797]. Modified-release CS formulations are prohibited.
4. Topi[INVESTIGATOR_35798]. No more than 1 oral NSAID may
be used during the study. Aspi[INVESTIGATOR_9022] (in addition to a single NSAID and topi[INVESTIGATOR_35799]) at stable doses no higher than 325 mg/day throughout the  study. NSAIDs may not
be used on an as-needed basis. Although regimens are required to be stable throughout the
study, NSAID dosing may be decreased or discontinued if due to NSAID toxicity. Adjustments
in NSAID regimens must be discussed with the  medical monito r.
5. Use of opi[INVESTIGATOR_35800] 3)e);
Section 5.2, are met.
6. Use of cyclophosphamide (including ophthalmic) or any IV, int rabursal, intratendinous sheath,
intramuscular, subcutaneous, intra-articular, or biologic agent  is prohibited. Required
discontinuation periods for immunomodulatory and biologic drugs  before the signing of
informed consent are provided in APPENDIX [ADDRESS_35401] dose.
Heat-killed or otherwise inactivated or protein vaccines such a s influenza and pneumococcal
vaccines may be received at any time on study. Any other inacti vated vaccines (eg, tetanus,
etc) should be used according to local guidelines during the TP (Exclusion Criterion 4)g);
Section 5.2).
8. Exposure to any investigational drug or placebo within 12 wee ks or 5 half-lives (whichever is
longer) before screening is prohibited (Exclusion Criterion  3)f); Section 5.2)
9. Use of any other drugs, including OTC medications and herbal preparations, within [ADDRESS_35402] dose of study treatment is prohibited, except medications cleared by [CONTACT_35041]
6.7.2 Existing Therapi[INVESTIGATOR_35801](s) duri ng the study (if the treatment 
complies with the eligibility criteria; Section 5 ). The dose and regimen of background SLE 
treatments must not change during study participation. Details of permissible therapi[INVESTIGATOR_35802]:
xAt least 1 background agent as specified in Inclusion Criterion  3)a) (Section 5.1 ); use of more
than 1 immunosuppressant in combination is NOT permitted.
xCS therapy with prednisone or equivalent as specified in Inclus ion Criterion 3)b) (Section 5.1 );
see restrictions in Section 6.7.1 . CS tapering  are described in
Sections 6.7.3
xChronic NSA ID ther
apy as specified in Inclusion Criterion  3)c) (Section 5.1 )
xStable preexisting topi[INVESTIGATOR_35803]  3)b) ( Section 5.1)
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 576.7.[ADDRESS_35403] be stable for 2 weeks before 
the screening visit (signing of informed consent) and throughou t the SP until randomization. Up 
to 30 mg/day prednisone or equivalent is permitted during the SP (and for the preceding 2 weeks). 
Rules for CS tapering are as follows:
xTapering of CS may begin at any tim e after the first dose of IP  on Day 1.
xFor subjects receiving > 7.5 mg/day prednisone or equivalent, tap ering must start by 
[CONTACT_10585] 8.
xFor all subje cts, the CS dose must be ‚â§ 7.5 mg prednisone or equivalent by [CONTACT_10585] 20 (if 
this is not possible, the subject will remain on treatment, but  will be a nonresponder for 
analysis purposes).
xInvestigators must assess the subject‚Äôs suitability for CS tape r at eac h visit (taper is not 
required to start until Week 8), and the last day for CS taper i s the Week [ADDRESS_35404] be tapered (beginning by [CONTACT_10585] 8 and continuing until the Week 20 visit) 
unless any of the following are observed:
oNew or worse BILAG or SLEDAI-2K activity for any of the followin g parameters: 
central nervous system, vasculitis, myositis, cardiorespi[INVESTIGATOR_696] , gastrointestinal, 
ophthalmologic, renal, or thrombocytopenia
oNew or worsening hemolytic anemia
oCLASI activity score ‚â• [ADDRESS_35405] remain s table from Week 40 until 
Week 48.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 586.[ADDRESS_35406] to enroll, BMS will continue to provide study treatment 
via Protocol IM011074, which is an LTE of the current study. Participation in IM011074 is not required for participation in this study, however.
BMS reserves the right to terminate access to BMS-supplied study treatment if any of the following 
occur: a) the study is terminated due to safety concerns; b) th e development of BMS-986165 is 
terminated for other reasons, including but not limited to lack  of efficacy and/or not meeting the
study objectives; c) the subject can obtain medication from a g overnment sponsored or private 
health program. In all cases B MS will follow local regulations
[ADDRESS_35407] discontinue the IP (and non-IP at the discretion of the investigator) for any of the 
following reasons:
xA subject requests to stop study treatment. Subjects who reques t to discontinue study 
treatment will remain in the study and must continue to be foll owed for protocol-specified 
follow-up procedures. The only exception to this is when a subj ect specifically withdraws 
consent for any further contact [CONTACT_35859]/her or persons previou sly authorized by [CONTACT_35860], laboratory abnormality, or intercurrent illness that, in the opi[INVESTIGATOR_1070], indicates that continued participation in the stu dy is not in the best interest of 
the subject
xTermination of the study or a specific dose group (for subjects  receiving that dose) by [CONTACT_35861] o r involuntary incarceration 
for treatment of either a ps ychiatric or physical (eg, infectio us disease) illness
xUnblinding of a subject‚Äôs treatment assignment for any reason ( emergency or 
nonemergency)
xPregnancy
xAbnormal liver tests suggestive of drug-induced liver injury (D ILI) as defined in 
Section 8.3.[ADDRESS_35408].
Refer to the Schedules of Activities ( Section 1.3 ) for data to be collected at the time of treatment 
discontinuation and follow-up a nd for any further evaluations t hat can be completed.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 59In the case of pregnancy, the investigator must immediately not ify the  medical monitor or 
designee of this event. In the event a normal healthy female subject becomes pregnant during a 
clinical trial, the study treatment must be discontinued immedi ately. In most cases, the study 
treatment will be permanently discontinued in an appropriate ma nner (eg, dose tapering if 
necessary for subject safety). Please call the  medical moni tor within 24 hours of awareness 
of the pregnancy. If the investigator determines a possible favo rable benefit/risk ratio that warrants 
continuation of study treatment, a discussion between the inves tigator and the  medical 
monitor must occur.
All subjects who discontinue study treatment should comply with  protocol-specified follow-up 
procedures as outlined in Section 1.[ADDRESS_35409]-treat ment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily i ncarcerated for the treatment of either 
a psychiatric or physical illness). Subject replacement is not permitted.
If study treatment is discontinued prior to the subject‚Äôs compl etion of the study, the reason for the 
discontinuati on must be documented in the subject‚Äôs medical records and ente red on the 
appropriate eCRF page.Subjects who discontinue study t reatment will remain in the stu dy for continued follow-up
.
7.[ADDRESS_35410] to discontinue study treatment (possible c ircumstances are listed in 
Section 7.1) will remain in the study and must continue to be followed for  protocol-specified 
follow-up procedures. The only exception to this is when a subj ect specifically withdraws consent 
for any further contact [CONTACT_35859]/her or persons previously auth orized by [CONTACT_35862]. 
xSubjects should notify the investigator of the decision to with draw consent from future 
follow-up in writing, whenever possible.
xThe withdrawal of consent should be explained in detail in the medical records by [CONTACT_35863].
xIn the event that vital status (whether the subject is alive or  dead) is being measured, 
publicly available information should be used to determine vita l status only as 
appropriately directed in accordance with local law.
xIf the subject withdraws consent for disclosure of future infor mation, the Sponsor may 
retain and continue to use any data collected before such a wit hdrawal of consent.
7.[ADDRESS_35411] continue to be followed for co llection of  survival 
follow-up data as required and in line with Section 3 until death or the conclusion of the study. 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 607.[ADDRESS_35412]‚Äôs medical 
records.
xIf it is determined that the subject has died, the site will us e permissible local methods to 
obtain date and cause of death.
xIf investigator‚Äôs use of third -party representative to assist in the follow-up portion of the  
study has been included in t he subject‚Äôs informed consent, then the investigator may use a 
Sponsor retained third- party representative to assist site staff with obtaining subjec t‚Äôs 
contact [CONTACT_35864]-up 
portion of the study. 
xThe site staff and representative will consult publicly available sources, such as public health registries and databases, to obtain updated contact [CONTACT_35865].
xIf after all attempts, the subject remains lost to follow-up, t hen the last known alive date as 
determined by [CONTACT_093] s hould be reported and documente d in the subject‚Äôs medical 
records.
7.[ADDRESS_35413] replacement is not permitted.
8 STUDY ASSESSMENTS AND PROCEDURES
Study procedures and timing are summarized in the Schedules of Activities (Section 1.3). Waivers 
or exemptions from protocol-required evaluations are not allowe d.
8.[ADDRESS_35414] be made to ensure that the same evaluator(s) complete the 
assessment for each subject. If the evaluator(s) is unable to c omplete the evaluation, then a 
qualified individual with overlappi[INVESTIGATOR_35804] e evaluation. Documentation of 
who performed the evaluation is to be recorded in source docume nts. Assessments are to be 
performed at approximately the  same time of day throughout the duration of the study.
Baseline assessments must be performed per protocol (standard o f care assessments may not be 
used for baseline). Procedures not specified in the protocol th at are part of standard care may be 
performed if they do not interfere with study procedures; any da ta arising from such procedures 
are not to be reported in the eCRF.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 61Note: NSAIDs must be withheld for at least 12 hours before visit s at which BILAG, SLEDAI-2K,
joint counts, CLASI, or Physician‚Äôs Global Assessme nt of Disease Activity are assessed (ie, all 
scheduled visits). Study treatment must not be taken on visit d ays until after efficacy assessments.
The following procedures or tools will be used to assess subjec ts‚Äô SLE disease activity during the 
study (see schedule in  Section 1.3 ):
xBILAG-200410,11,12,13(APPENDIX 10 ): The BILAG-2004 rating is based on organ systems 
(constitutional, mucocutaneous, neuropsychiatric, musculoskelet al, cardiorespi[INVESTIGATOR_696], 
gastrointestinal, ophthalmic, r enal, and hematological). Each is scored by a number of 
assessments, from which an overall grade is derived for each organ system. The overall grades 
are represented as 5 different levels from A to E (A = very active, B = moderate disease activity, C = mild stable disease, D = no disease activity but suggests the system had previously 
been affected, and E = no current or previous disease activity) .
xSLEDAI-2K
14,15(APPENDIX 11 ): The SLEDAI-2K is a global index based on weighted 
scores for each of [ADDRESS_35415] 30 days. The SLEDAI-2K assigns relative weights to each pa rameter.
xCLASI  16,17(APPENDIX 12 ): The CLASI assesses cutaneous disease activity by [CONTACT_35866]; points are given for presence of erythema, scale, hypertro phy, mucous membrane lesions, 
recent hair loss, and physician-observed alopecia. For the dama ge assessments, points are 
given for dyspi[INVESTIGATOR_371], scarring, and scarring alopecia.
x40-joint count: A 40-joint count is used. This includes bilater al wrists, elbows, ankles, knees, 
interphalangeal joints of the thumb, individual proximal interp halangeal joints of the hand, 
second through fifth metacarpophalangeal joints of the hand, an d individual 
metatarsophalangeal joints of the feet (which make up the 36-joi nt count) .18,19,20To allow the 
28-joint count evaluation, bilateral first metacarpophalangeal joints and shoulders are also 
included, bringing the total joint count to 40. Each joint is e valuated based upon the presence 
or absence of tenderness, the presence or absence of swelling, and the presence or absence of 
both tenderness and swelling.
xPhysician‚Äôs Global Assessment of Disease Activity assessed using a 3 -point visual analog scale 
(VAS).
The following composite measures will be determined based on so me of the assessments described 
above:
xBICLA response21as defined in Section [IP_ADDRESS]
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 62xSLE Responder Index22(SRI): The SRI is a composite endpoint that defines a responder  as a 
patient whose disease course fulfills all of the following:
oA predefined reduction (number of points) from baseline in SLED AI-2K score14,15
(APPENDIX 11 ). The SRI can be calculated based on the number of points of reduction in 
the SLEDAI-2K (SRI[4], SRI[5], SRI[6], and SRI[7]).
oNo new BILAG A (severe disease activity) or not more than 1 new  BILAG B (moderate 
disease activity) organ domain grade
oNo worsening from baseline in th e Physician‚Äôs Global Assessment  of Disea se Activity 
scale by [CONTACT_726] 0.3 points
xLupus Low Disease Activity State (LLDAS):23,24LLDAS is defined as follows: 
(1) SLEDAI- 2K ‚â§ 4, with no activity in major organ systems (renal, central nerv ous system, 
cardiopulmonary, vasculitis, feve r) and no hemolytic anemia or gastrointestinal activity 
(measured as maintaining a D or E  score in the BILAG Gastrointe stinal Body System); (2) no 
new lupus disease activity compared with the previous assessmen t measured as no new or 
worsening individual BILAG parameters; (3) Physician‚Äôs Global A ssessment of Disease 
Activity ‚â§ 1; (4) a current prednisolone (or equivalent) dose ‚â§ 7.5 mg daily; and 
(5) well-tolerated standard maintenance doses of immunosuppressi ve drugs and approved 
biological agents.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 638.2 Laboratory Assessments Related to SLE Disease Activity
The following laboratory tests will be performed according to the schedule in Section 1.3 to gather 
more information about SLE disease activity: Coomb‚Äôs test (dire ct); serum complement (C3, C4); 
quantitative immunoglobulins (IgG, IgA, IgM); anti-dsDNA; anti- Sm; ANA; anti-Ro (SSA); 
anti- La (SSB); anti-ribonucleoprotein (RNP); T cells, B cells, and natural killer cells (TBNK); 
and high-sensitivity C-reactive protein. Laboratory assessments  that are used in some efficacy 
assessments (eg, BILAG and SLEDAI-2K), such as complete blood c ount and renal function tests, 
are also used for safety assessments and are described in Section 8.5.3 . Samples for confirmation 
of hemolysis (using haptoglobin and reticulocyte count) for the  BILAG will be drawn at 
assessment visits and stored at the central laboratory; the samples will only be analyzed if there is 
clinical suspi[INVESTIGATOR_35805].
8.[ADDRESS_35416] (or, when approp riate, by a caregiver, surrogate, or 
the subject‚Äôs legally authorized representative). 
The investigator and any designees are responsible for detectin g, documenting, and reporting 
events that meet the definition of an AE or serious adverse eve nt (SAE) and remain responsible 
for following up AEs that are serious, considered related to th e study treatment or the study, or 
that caused the subject to discontinue before completing the study.The definitions of an AE or SAE can be found in APPENDIX 3 .
Contacts for SAE reporting are specified in Appendix 3 .
The event (term), along with its start and stop dates, maximum intensity (mild, moderate, or 
severe), seriousness (yes/no), relationship to the IP (yes/no),  action taken with regard to the IP, 
and outcome will be recorded in the eCRF.8.3.[ADDRESS_35417] (AEIs) are AEs for a particular prod uct or class of products that a 
Sponsor may wish to monitor carefully. Adverse events of intere st may be serious or nonserious. 
Such events may require further investigation to better charact erize and understand them. In the 
BMS-986165 clinical development program, certain skin-related A Es (eg, acne) and infection AEs 
have been identified as potential AEIs; however, there has been  no definitive assessment on the 
causal relationship between these events and treatment with BMS-986165. Therefore, additional 
information about certain AEs may be collected on the eCRF in o rder to better characterize and 
understand them.
8.3.[ADDRESS_35418] follow-up visit, at the timepoints spec ified in the Schedules of Activities 
(Section 1.3).
The Reference Safety Information in Sections 5.6.[ADDRESS_35419]‚Äôs written consent to 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 64participate in the study, all SAEs, whether related or not rela ted to study treatment, must be 
collected, including those thought to be associated with protoc ol-specified procedures.
All SAEs that occur from the time the informed consent form (ICF ) is signed through [ADDRESS_35420] has been
discharged from the study, and he/she considers the event reaso nably related to the study treatment 
or study participation, the investigator must promptly notify t he Sponsor.
The method of evaluating and assessing causality of AEs and SAE s and the procedures for 
completing and reporting/transmitting SAE reports are provided inAPPENDIX [ADDRESS_35421] (or, when appropriate, by a caregiver, surrogate, or the subject‚Äôs legally authorized representative). Nonserious SLE-related AEs will be collected o nly on the disease assessment 
instruments and not reported as AEs.
All AEs and SAEs that arise in the study will be reported and i nvestigated. However, because of 
the characteristics of the disease under study and of BMS-[ZIP_CODE] 5 itself, subjects will be more 
closely monitored for signs of infection and for treatment-emergent rash ( Section 8.3.9 ).
8.3.4 Follow-up of AEs and SAEs
xNonserious AEs should be followed to resolution or stabilizatio n, or reported as SAEs if
they become serious (see  APPENDIX 3 ).
xFollow-up is also required for nonserious AEs that cause interr uption or discontinuation of 
study treatment and for those prese nt at the end of study treatment as appropriate.
xAll identified nonserious AEs must be recorded and described on  the nonserious AE page 
of the CRF. Completion of supplemental CRFs may be requested fo r certain AEs, such as 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 65skin reactions and infections, and/or laboratory abnormalities that are reported/identified 
during the course of the study.
After the initial AE/SAE report, the investigator is required t o proactively follow each subject at 
subsequent visits/contacts. All SAEs will be followed until res olution, until the condition 
stabilizes, until the event is otherwise explained, or until th e subject is lost to follow-up (as defined 
inSection 7.4).
Further information on follow-up procedures is given in APPENDIX 3.
8.3.[ADDRESS_35422] under clinical investigation are met.
xAn investigator who receives an investigator safety report describing SAEs or other 
specific safety information (eg, summary or listing of SAEs) fr om the Sponsor will file it 
along with the IB and will notify the institutional review boar d (IRB)/independent ethics 
committee (IEC), if appropriate according to local requirements .
The Sponsor or designee will be reporting AEs to regulatory aut horities and ethics committees 
according to local applicable laws including European Directive  2001/20/EC and Food and Drug 
Administration Code of Federal Regulations [ADDRESS_35423] cases, the study treatment will be permanently disconti nued in an appropriate manner (eg, 
dose tapering if necessary for subject safety).
Any pregnancy that occurs in a female partner of a male study s ubject should be reported to  
Drug Safety. For the Sponsor or designee to collect any pregnancy surveillance information from 
the female partner, the female partner must sign an ICF for disc losure of this information. 
Information on this pregnancy will be  collected on the Pregnanc y Surveillance Form.
Protocol-required procedures for s tudy discontinuation and foll ow-up must be performed on
subjects who become pregnant.
Follow-up information regarding the course of the pregnancy, in cluding perinatal and neonatal 
outcome and, where applicable, offspring information must be re ported on the Pregnancy 
Surveillance Form.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 668.3.[ADDRESS_35424] result abnormality that required the subjec t to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than  laboratory term would be used by [CONTACT_35867] (eg, anemia versus low hemoglobin value) .
8.3.8 Potential Drug-Induced Liver Injury
Wherever possible, timely confir mation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a  potential DILI event. All occ urrences of potential DILIs, meeting 
the defined criteria, mus t be reported as SAEs (see  APPENDIX 3 for reporting details).
Potential DILI is defined by [CONTACT_35868]:
xALT or AST elevation > 3√ó ULN
xtotal bilirubin > 2√ó ULN, without initial fi ndings of cholestasis (elevat ed serum alkaline
phosphatase)
xno other immediately apparent possible causes of AST or AST elevation and
hyperbilirubinemia, including, but not limited to, vi ral hepatitis, pre existing chronic or
acute liver disease, or the administration of other drug(s) know n to be hepatotoxic
8.3.9 Other Safety Considerations
Any significant worsening noted during interim or final physica l examinations, ECG, X-ray 
filming, any other potential safety assessment required or not required by [CONTACT_35869] a nonserious or serious AE, as appropriate, and rep orted accordingly.
8.4 OverdoseFor this study, any dose of blinded study treatment that is mor e than 2- days‚Äô worth of study 
treatment within a 24-hour time period will be considered an ov erdose. 
In the event of an overdose the investigator should:
1. Contact [CONTACT_35870].
2. Closely monitor the subject for AEs/SAEs and laboratory abnormalities until BMS-986165 
can no longer be detected systemically (at least 3 days).
3. Document the quantity of the excess dose as well as the durat ion of the overdosing in the eCRF.
Decisions regarding dose interruptions or modifications will be  made by [CONTACT_35871].
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 678.5 Safety
Planned timepoints for all safety assessments are listed in the  Schedules of Activities
(Section 1.3). All urgent safety concerns must be discussed with the Sponso r immediately upon 
occurrence or awareness to determine if the subject should cont inue or discontinue treatment.
Safety evaluations that will be performed in addition to AE mon itoring are physical examinations 
(PE; Section 8.5.1), TB screening ( Section 8.5.2), vital signs, ECGs, concomitant medication 
use, and laboratory tests ( Section 8.5.3).
8.5.1 Physical Examinations
Schedules for PEs are provided in Section 1.3 .Complete and/or targeted PEs may be performed 
by a Doctor of Medicine (MD), or someone who is authorized to p erform the examinations by 
[CONTACT_35872]. While the targeted 
examination may not be as comprehensive as the initial full exa mination, key aspects should 
evaluate important body systems as clinically indicated. These body systems can include lymph 
nodes, liver, spleen, and breast at the discretion of the examin er. A targeted examination may note 
any changes in the subject‚Äôs condition (body systems) since the  last assessment and does not 
preclude examination of any of the other body systems as clinically indicated. Every effort should 
be made to ensure the same evaluator will complete the examinat ion for each subject at all visits 
throughout the study. Documentation of who performed the examin ation is to be recorded in source 
notes.
8.5.[ADDRESS_35425]‚Äôs eligibi lity as defined in 
Section 5.2, Exclusion Criterion 4a, and outlined in Section 1.[ADDRESS_35426], an IGRA (eg, T-spot¬Æor QuantiFERON¬Æ), preferably performed centrally. If 
unable to obtain central laboratory results (eg, repeated test due to indeterminate result), an IGRA 
test could be obtained locally, after consultation with the  medical monitor.
8.5.3 Clinical Safety Laboratory Assessments
A central laboratory will perform assessments of safety laborat ory assessments (except pregnancy 
tests) and provide reference ranges and laboratory reports. Inv estigators must document their 
review of each laboratory safety  report. Any laboratory test re sult that the investigator considers 
clinically relevant is to be recorded on the appropriate AE pag e of the eCRF ( Section 8.3.7 ). 
Results of clinical laboratory tests performed during screening must be available prior to 
randomization. Additional safety assessments may be performed at local laboratories at the 
investigator‚Äôs discretion. The laboratory parameters to be asse ssed are as follows:
xHematology: hemoglobin, hematocrit, total leukocyte count (including d ifferential), 
platelet count, RBC count, and manua l differential (separate sm ear)
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 68xChemistry: AST, ALT, gamma gluta myltransferase, total bilirubin , direct bilirubin, 
alkaline phosphatase, lactate dehydrogenase, creatinine, blood urea nitrogen, uric acid, 
fasting glucose, total protein, albumin, sodium, potassium, chl oride, calcium, phosphorus, 
magnesium, creatine kinase, creatinine clearance (screening onl y)
xCoagulation: prothrombin time, INR, and either partial thrombop lastin time or activated 
partial thromboplastin time
xTSH (screening only)
xTests performed after a ‚â• 10-hour fast: lipid panel (total cholesterol, high-density 
lipoprotein cholesterol, low-density lipoprotein cholesterol, a nd triglycerides), plasma 
glucose
xUrinalysis: protein, glucose, blood, leukocyte esterase, specif ic gravity, pH; microscopic 
examination of the sediment if blood, protein, or leukocyte est erase are positive on dipstick; 
spot urine will be assessed for urine protein and urine creatin ine
xSerology to be performed at screening: hepatitis C antibody, HBsAg, anti-HBc, HIV-1 and HIV-2 antibody, TB (screening only)
In addition, urine pregnancy testing will be performed for WOCB P, and follicle-stimulating 
hormone will be measured to confirm postmenopausal status (as app licable; at screening only).
8.5.4 Imaging Safety Assessment
Not applicable.
8.6 Pharmacokinetics
The PK of BMS-986165 and metabolites (if applicable) will be de rived from plasma concentration 
versus time. 
Plasma samples will be analyzed for BMS-[ADDRESS_35427] PK parameter values will be derived by [CONTACT_35873] a 
validated PK analysis program. Actual times will be used for the analyses. In addition, plasma 
samples will be archived for potential metabolites analysis, if the need arises and to the extent 
possible. Detailed instructions for PK blood collection, labeli ng, processing, storage, and shippi[INVESTIGATOR_35806].
The PK parameters to be assessed include:
Cmax Maximum observed plasma concentration
Tmax Time of maximum observe d plasma concentration
Ctrough Trough observed plasma concentration
The area under the concentration-time curve in one dosing interval (AUC[TAU]) will be calculated 
if possible.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 698.6.[ADDRESS_35428] (for Day 1 and Day 85 visits) of at 
least 10 hours. As described in Secti on 1.3 , the timing of other procedures at a given visit can be 
adjusted so that PK sampling can be performed at the scheduled time. If possible, PK samples 
should be collected for subjects  who discontinue treatment due to an AE. Further details of blood 
collection and processing are provid ed to sites in the Study Re ference Manual.
Table 7: PK and PD Sampling Schedule for BMS-986165 and BMT-153261
Study Day 
of Sample 
CollectionEventTime
(Relative To 
Dose) 
Hour: MinBlood 
Sample 
for PKBlood 
Sample 
for IRGNotes
1 predose 00:[ADDRESS_35429] has been 
fasted for ‚â• 10 hours (fasting is required for other 
assessments at this visit as well). However, subjects 
may eat after the Hour 2 sample has been collected.1 00:30 X
1 02:00 X
15 predose 00:00 X X
29 predose 00:00 X X
57 predose 00:00 X X
85 predose 00:[ADDRESS_35430] has been 
fasted for ‚â• 10 hours (fasting is required for other 
assessments at this visit as well). However, subjects 
may eat after the Hour 4 sample has been collected.85 00:30 X
85 02:00 X X
85 04:00 X X
85 06:00 X X
113 predose 00:00 X
141 predose 00:00 X
169 predose 00:00 X X
197 predose 00:00 X
225predose 00:00 X X An aliquot of collected blood sample will be included 
for potential measurement of concomitant medication.
253 predose 00:00 X
281 predose 00:00 X
309 predose 00:00 X
337 predose 00:00 X X
IRG = interferon-regulated gene; PD = pharmacodynamic(s); PK = pharmacokinetic(s)
Note: Predose samples must be drawn before the morning dose of study treatment on the visit day, ie, study treatment will 
be taken at the site on those days.
8.6.[ADDRESS_35431] PK samples at the times indicated. However, for 
flexibility in PK sampling, the following windows serve as a guideline for PK sample collection:
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 70xPredose samples must be drawn before the morning dose on the visit day.
xThe following windows apply to other samples:
o¬±0.25 hour for the 0.5-hour sample
o¬±0.5 hour for the 2-hour sample
o¬± [ADDRESS_35432] be noted in the source documents .
Pharmacodynamic sampling will follow the same time window as PK  and will be collected at 
matched PK timepoints.
8.7 Supplemental Assessments: Photography
Sites will be equipped with clinical photography supplies.  will use the photographs to assist 
in establishing appropriate use of the CLASI instrument for sel ected visits. Additionally, the 
photographs will be used to help distinguish a rash related to SLE from a rash arising as a side 
effect of the study treatment. Any photographs may be used as supplemental documentation for 
publications and to increase understanding of cutaneous manifes tations of interest. Appropriate 
measures will be applied to ensure subject privacy. Details of study photography are provided in 
the Central Photography Manual. Only subjects who consented to photography will be 
photographed.
8.8 Pharmacogenomics
Not applicable
8.9 Biomarkers
Details of blood and urine collection and processing will be pr ovided to the site in the Study 
Reference Manual. Biomarker samples will generally be collected  from all study subjects (with 
the exception of Day 2 or 3 samples). Blood and urine will be c ollected at the timepoints shown in 
Section 1.[ADDRESS_35433]; 
however, the aggregated results may be shared. The aggregated r esults may be published to further 
the understanding of BMS-986165 or lupus; however, individually  identifiable patient data will 
not. The end of the study for biomarker samples is defined as u p to the maximum allowed in the 
individual ICF documents. Although the analysis of some biomark ers will be performed 
immediately, additional biomarker analysis may be delayed while  the initial analysis of the study 
results are interpreted and integrated.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 718.9.[ADDRESS_35434] for potential differences in
subjects‚Äô response to BMS -986165 and CS treatment.
8.9.2 Pharmacodynamics and Mechanism of Action
The PD effects of BMS-986165 will be assessed based on markers in blood and urine, which will 
be collected at the timepoints shown in Section 1.3 and in Table 7 . Serum and plasma samples will 
be collected and analyzed for markers of tissue damage and regeneration, such as markers of 
inflammatory damage to collagen. Samples will be collected predose except for the FP visit. 
Samples can also be collected a t any time for the Day 2 or 3 sa mple, which will be collected for a 
subset of subjects for blood ribonucleic acid (RNA) and inflamm atory markers (this will be 
performed in a home visit or other means to avoid requiring sub jects to return to the site).  
 
Lupus is an inflammatory/autoimmune disorder that results in da mage to many different tissues. 
It is characterized by [CONTACT_35874] I IFN pa thway. To assess the effect of 
BMS-[ADDRESS_35435] decreases in complement prot eins, C3 and C4, and circulating 
lymphocytes. These will be assessed for evidence of PD activity . Anti-dsDNA will also be 
assessed for PD changes in serum and plasma.
BMS-986165 is expected to inhibit the actions of IL-12 and IL-2 3. This should result in alterations 
to T-helper cell phenotypes. In addition, B-cell populations ar e dysregulated in lupus, with 
increases in activated phenotypes.  Blood will be collected for lymphocyte profiling including 
assessments of T-helper subpopulations, activated and memory T- cell subpopulations, B-cell 
populations, and dendritic cell populations. These populations will be enumerated in samples from 
a subset of subjects in the [LOCATION_003]. In addition, the effects of BMS-986165 on IL-12- and 
IL-23-regulated genes and proteins will also be assessed.
Corticosteroid treatment is common in lupus; however, the effectiveness of this treatment varies 
in different patients. Thus, a broad range of doses are used ac ross patient populations and even 
over time within individual patients. This treatment can confou nd the interpretation of 
investigational clinical trials. To address this issue, the bio logical effect of CS use will be assessed 
by [CONTACT_35755] a gene signature [CONTACT_35898].
Lupus patients have characteristic alterations in blood cell pop ulations and activation status. Blood 
samples will be collected to assess the numbers and activation status of lymphocyte and leucocyte 
cell subsets.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 729 S
TATISTICAL CONSIDERATIONS
9.1 Sample Size Determination 
Approximately 360 subjects will be randomized into 1 of 4 treatment arms in a 1:1:1:1 ratio, 
resulting in around 90 subjects per arm.  
 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential [ADDRESS_35436] 84% power to detect a treatment difference of 20% in SRI(4) response rates between 
the BID BMS-986165 treatment arms and placebo  
 
 
9.2 Populations for Analyses
The following populations are defined for analysis purposes:
Population Description
Enrolled All subjects who sign informed consent.
Randomized All subjects who are randomized to a treatment. Subjects will b e 
grouped according to the treatment to which they are randomized  
according to IRT at the start of the TP.
Modified intent-to-treat 
(mITT)All subjects who are randomized and have received at least [ADDRESS_35437] 1 dose of double-blind study 
treatment, analyzed according to the treatment actually receive d, 
regardless of assigned treatment. 
Per Protocol Set (PPS) All subjects who are compliant with study treatment (compliance  
criteria will be defined in the SAP) and who do not have any 
relevant protocol deviations that may impact the primary effica cy 
endpoint assessments. The PPS will be a supportive efficacy 
analysis population.
9.3 Statistical AnalysesThe SAP will be developed and finalized before database lock fo r the primary efficacy analysis 
and will provide detailed specifications of the analysis of all efficacy endpoints and safety, and it 
will also describe the selection of subjects to be included in the analyses and procedures for 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 74accounting for missing data. This section provides a summary of  planned statistical analyses of 
the primary and secondary endpoints. 
9.3.1 Efficacy Analysis 
[IP_ADDRESS] Endpoints
Primary Efficacy Endpoint
The primary efficacy endpoint is:
xProportion of subjects who meet SRI(4) response at Week 32 (SRI response is defined 
inSection 8.1 )
Secondary Efficacy Endpoints
Secondary efficacy endpoints are as follows:
xProportion of subjects who meet SRI(4) response at Week 48
xProportion of subjects who achieve BICLA response at Week 48, where BICLA  
response is defined as follows:
xImprovement in all organ systems with activity graded as BILAG-2004 A or B at 
baseline
xNo new organ system with activity graded as BILAG A; no more than 1 new
organ system with activity graded as BILAG B
xNo increase from baseline in SLEDAI-2K (‚â§0 points for change from baseline 
score)
xNo increase ‚â• 10% in the Physician‚Äôs Global Assessment of Disease Activity
on a 3-point VAS
xNo discontinuation of IP or use of restricted medications beyond the
protocol allowed threshold before assessment
xProportion of subjects who achieve LLDAS at Week 48
xProportion of subjects with a CLASI activity score ‚â• 10 at baseline who achieve a 
CLASI response, defined as a decrease of ‚â• 50% from baseline CLASI activity score at 
Week 48
xChange from baseline in the 40-joint count for tender, swollen,  and tender + swollen 
joints at Week 48
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential [IP_ADDRESS] N
onresponders
Subjects will be considered nonresponders in the TP for the res ponder-type efficacy endpoints 
(ie, BICLA and SRI) in the primary and secondary analyses at we eks 32 and 48, respectively, 
if they meet any of the following criteria:
xRequires CS dose > 7.5 mg/day pre dnisone or equivalent after Week [ADDRESS_35438]  of CS rescue therapy
xRequires dose increase in background immunosuppressant or antim alarial medication
xRequires treatment with medications prohibited by [CONTACT_760] (Section 6.7.1 and 
APPENDIX 7)
xDiscontinues treatment before the assessment timepoint or has a missing value for the 
particular endpoint
Nonresponder definitions for other time points will be provided  in the SAP.
[IP_ADDRESS] Analysis Methodology
General Summaries
Summaries will be provided for t he following efficacy variables  by [CONTACT_35875], in addition to the above endpoints:
xProportion of subjects who:
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 76xMeet SRI(4) response criteria
xMeet BICLA response criteria
xMeet LLDAS response criteria
xHave a CLASI activity score ‚â• 10 at baseline who achieve a CLASI response, 
defined as a decrease of ‚â• 50% from baseline CLASI activity score
xAre receiving a daily CS dose ‚â§ 7.5 mg/day prednisone (or equivalent) in those 
receiving CS at baseline
xChange from baseline in:
xBILAG-2004 score
xSLEDAI-2K score
xJoint counts for tender, swollen, and tender + swollen joints
xPhysician‚Äôs Global Assessment of Disease Activity
xCLASI activity score in subjects with a CLASI activity score ‚â• 10 at baseline
Statistical Methodology
Efficacy analyses will be pe rformed using the population of randomized subjects.
Endpoint Statistical Analysis Methods
Primary The primary endpoint, the proportion of subjects who meet the r esponse 
criteria for SRI(4) at Week 32, will be analyzed using logistic regression 
with covariate for the randomization stratum to compare the res ponse rates 
between each treatment group and placebo. The odds ratio (odds for active 
treatment /odds for placebo) and the corresponding 2 -sided 95% confidence 
interval (CI) will be provided from the logistic regression mod el. 
Additionally, a sensitivity analysis will be conducted using a Cochran-
Mante l-Haenszel (CMH) chi-square test stratified by [CONTACT_35876];
or alternatively a chi -square test if a CMH test cannot be performed. 
Differences in response rates and corresponding 2 -sided 95% CI will be 
provided along with the point estimates and corresponding 95% C I for each 
group using a binomial model.
The above analyses will be conducted for the mITT population. T he primary 
efficacy analysis will be perfor med after all subjects have com pleted 
Week 48 efficacy assessments (or discontinued).
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 77Endpoint Statistical Analysis Methods
Secondar Similar analyses will be performed as for the primary efficacy analyses for 
the proportion -type secondary  efficacy endpoints to compare 
differences between the active treatment groups and placebo.
The response rates over time will be analyzed using a repeated m easure 
model when applicable.Repeated continuous measures will be analyzed using a mixed eff ect model 
with treatment, visit, treatment
-by-visit interaction, and randomization 
stratum as the fixed effects and changes from baseline within each subject as 
the repeated measurements. The baseline value will be added int o the model 
as a covariate. Based on the mixed effect model, the point esti mate, and 95% 
CI will be calculated for the diff erence between each active tr eatment group 
and the placebo group at each specified visit. 
All analyses will be conducted for the mITT population. The han dling of 
missing values will be described in the SAP.
 
Additionally, subgroup a
nalyses to be performed will be describ ed in the SAP.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 78
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 799.3.[ADDRESS_35439] results 
will be listed and summarized by [CONTACT_3148]. ECG readings will b e evaluated by [CONTACT_35877], if present, wil l be summarized and listed.
9.3.3 Other Analyses 
[IP_ADDRESS] Pharmacokinetics
PK evaluation is a secondary endpoi nt. Plasma concentration val ues will be summarized by [CONTACT_35878]. If warranted, analy sis of PK and exposure-response 
relationships of BMS-986165 will be conducted using a populatio n approach as appropriate and 
reported separately from the clinical study report.
[IP_ADDRESS] Pharmacodynamics
Pharmacodynamic evaluation is a secondary endpoint. Selected PD  endpoints such as IRG 
expression, C3, C4, and anti-dsDNA will be summarized by [CONTACT_11139], and their 
corresponding changes and percent change from baseline will be calculated and summarized. 
Change from baseline in lymphoc yte count, serum or plasma prote ins, genome-wide RNA 
expression, lymphocyte subsets and activation status, etc, will  be summarized by [CONTACT_5586]. Baseline 
values will be defined as the last measurement before the first  dose.
9.3.[ADDRESS_35440] 50% of sub jects have achieved the Week [ADDRESS_35441] completed 48 weeks of 
double-blind treatment (or have discontinued) and the 4-week sa fety follow-up for those who have
not enrolled into the LTE study IM011074. Details of these effi cacy and safety analyses will be 
described in the SAP.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential [ADDRESS_35442] WT, Hissong BD, Bream JH, et al. Signaling by [CONTACT_8668]-12 and IL-23 and the 
immunoregulatory roles of STAT4. Immunol Rev 2004;202:139-56.
2. Tokarski JS, Zupa-Fernandez A, Tredup JA, et al. Tyrosine kin ase 2-mediated signal 
transduction in T lymphocytes is blocked by [CONTACT_35879]. J Biol Chem 2015;290(17):[ZIP_CODE]-74.
3. Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in t he Tyk2 pseudokinase 
domain underlies altered susceptibility of B10.Q/J mice to infe ction and autoimmunity. 
Proc Natl Acad Sci U S A 2003;100(20):[ZIP_CODE]-9.
4. Volpe E, Servant N, Zollinger R, et al. A critical function f or transforming growth factor-
beta, interleukin 23 and proinflammatory cytokines in driving a nd modulating human 
T(H)-17 responses. Nat Immunol 2008;9(6):650-7.
5. Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid 
cells are increased in inflammatory bowel disease. J Exp Med 2011;208(6):1127-33.
6. Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, 
randomized controlled trial comparing the safety and efficacy o f briakinumab with 
etanercept and placebo in patients with moderate to severe chro nic plaque psoriasis. Br J 
Dermatol 2011;165(3):661-8.
7. Characterization of Tyk2 inhibitor, BMS-986165, in biochemica l and human immune cell 
assays (Study IMM0043). Bristol-Myers Squibb Company; 2015. Doc ument Control No. 
930087619.
8. Brkic Z, Corneth OB, van Helden-Meeuwsen CG, et al. T-helper 17 cell cytokines and 
interferon type I: partners in crime in systemic lupus erythematosus? Arthritis Res Ther 
2014;16(2):R62.
9. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validati on of the Systemic Lupus 
International Collaborating Clinics classification criteria for  systemic lupus erythematosus. 
Arthritis Rheum 2012;64(8):2677-86.
10. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Developme nt and initial validation 
of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (O xford) 2005;44(7):902-
6.
11. Yee CS, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 
2004 index: a reliable tool for assessment of systemic lupus er ythematosus activity. 
Arthritis Rheum 2006;54(10):3300-5.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 8112. Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index 
is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 
2007;56(12):4113-9.
13. Yee CS, Cresswell L, Farewell V, et al. Numerical scoring fo r the BILAG-2004 index. 
Rheumatology (Oxford) 2010;49(9):1665-9.
14. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematos us disease activity index 
2000. J Rheumatol 2002;29(2):288-91.
15. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day wind ow. Lupus 
2010;19(1):49-51.
16. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous  Lupus Erythematosus 
Disease Area and Severity Index): an outcome instrument for cut aneous lupus 
erythematosus. J Invest Dermatol 2005;125(5):889-94.
17. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus 
disease area and severity index: a responsive instrument to mea sure activity and damage in 
patients with cutaneous lupus erythematosus. Arch Dermatol 2008 ;144(2):173-80.
18. Egger MJ, Huth DA, Ward JR, et al. Reduced joint count indic es in the evaluation of 
rheumatoid arthritis. Arthritis Rheum 1985;28(6):613-9.
19. Sokka T, Pi[INVESTIGATOR_35807] T. Quantitative joint assessment in rheumato id arthritis. Clin Exp 
Rheumatol 2005;23([ADDRESS_35443] 39):S58-62.
20. Fuchs HA, Brooks RH, Callahan LF, et al. A simplified twenty -eight-joint quantitative 
articular index in rheumatoid art hritis. Arthritis Rheum 1989;3 2(5):531-7.
21. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety  of epratuzumab in patients 
with moderate/severe active systemic lupus erythematosus: result s from EMBLEM, a 
phase IIb, randomised, double-blind, placebo-controlled, multic entre study. Ann Rheum 
Dis 2014;73(1):183-90.
22. Furie R, Petri MA, Strand V, et al. Clinical, laboratory and  health-related quality of life 
correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med 2014;1(1):e00003 1.
23. Franklyn K, Lau CS, Navarra SV, et al. Definition and initia l validation of a Lupus Low 
Disease Activity State (LLDAS). Ann Rheum Dis 2016;75(9):1615-2 1.
24. Golder V, Kandane-Rathnayake R, Hoi AY, et al. Frequency and  predictors of the lupus 
low disease activity state in a multi-national and multi-ethnic  cohort. Arthritis Res Ther 
2016;18(1):260.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 8235. Bre
tz F, Maurer W, Brannath W, et al. A graphical approach to sequentially rejective 
multiple test procedures. Stat Med 2009;28(4):586-604.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 8311 APPENDICES
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 84APPENDIX 1 STUDY GOVERN ANCE CONSIDERATIONS
The term ‚ÄòParticipant‚Äô is use d in the protocol to refer to a pe rson who has consented to participate 
in the clinical research study. The term ‚ÄòSubject‚Äô used in the eCRF is intended t o refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS 
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
xGood Clinical Practice (GCP)
xas defined by [CONTACT_25039] (ICH)
xin accordance with the ethical  principles underlying European U nion Directive 2001/20/EC
x[LOCATION_002] (US) Code of Federal Regulations, Title 21, Part 50 (21CFR50)
xapplicable local requirements
The study will be conducted in compliance with the protocol. The protocol a nd any amendments
and the participant informed consent will receive approval/favorable op inion by [CONTACT_35880]/Independent Ethics Committee (IRB/IEC), and regulato ry authorities according to
applicable local regulations pr ior to initiati on of the  study.
All potential serious breaches must be reported to Sponsor or designee imm ediately. A serious
breach is a breach of the conditions and principles of GCP in connection wit h the study or the
protocol, which is likely to affect, to a significant degree, the safety o r physical or mental integrity
of the subjects of the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by [CONTACT_35881] n, training, and
experience to perform their respective tasks.This study will not use the services of study personnel where sanctions hav e been invoked or where
there has been scientific misconduct or fraud (eg, loss of medic al licensure, debarment
).
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated app roval/favorable opi[INVESTIGATOR_35808]/IEC for the protocol, consent form, participant recruitment materials
(eg, advertisements), and any other written information to be provided t os u b j e c t s .T h e  
investigator or BMS should also provide the IRB/IEC with a copy of the Inves tigator Brochure or
product labeling information to be provided to subjects and any upd ates.
The investigator, Sponsor or designee should provide the IRB/IEC with rep orts, updates and other
information (eg, expedited safety reports, amendments, and administrat ive letters) according to
regulatory requirements or institution procedures.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONSThe investigator should not implement any deviation or change to the proto col without prior
review and documented approval/favorable opi[INVESTIGATOR_35809] e IRB/IEC (and if
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 85applicable, also by [CONTACT_14306]) except where necessary to eli minate an immediate
hazard(s) to study subjects.
If a deviation or change to a protocol is implemented to eliminate  an immediate hazard(s) prior to
obtaining relevant approval/favorable opi[INVESTIGATOR_1649](s) the deviation or chan ge will be submitted, as
soon as possible to:
xIRB/IEC 
xRegulatory Authority(ies), if applicable by [CONTACT_427] (per national requirements)
Documentation of approval/favorable opi[INVESTIGATOR_35810] o r designee of the
IRB(s)/IEC(s) and if applicable, also by [CONTACT_35882] b e sent to BMS.
If an amendment substantially alters the study design or increases the pot ential risk to the
participant: (1) the consent form must be revised and submitted to the IRB( s)/IEC(s) for review
and approval/favorable opi[INVESTIGATOR_1649]; (2) the revised form must be used to obta in consent from subjects
currently enrolled in the study if they are affected by [CONTACT_29991]; and (3) the new form must
be used to obtain consent from new subjects prior to enrollment .
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and sub-investigators will provide the Sponsor wi th sufficient, accurate financial 
information in accordance with local regulations to allow the S ponsor to submit complete and 
accurate financial certification or disclosure statements to th e appropriate health authorities. 
Investigators are responsible for providing information on fina ncial interests during the course 
of the study and for [ADDRESS_35444] ensure that subjects are clearly and fully i nformed about the purpose, potential
risks, and other critical issues regarding clinical studies in wh ich they volunteer to participate.
In situations where consent cannot be given to subjects, their legally ac ceptable representatives (as
per country guidelines) are clearly and fully informed about th e purpose, potential risks, and other
critical issues regarding clinical studies in which the participant  volunteers to participate.
Sponsor or designee will provide the investigator with an appropriate (ie, global or local) sample
informed consent form (ICF) which will include all elements required by I CH, GCP, and
applicable regulatory requirements. The sample ICF will adhere to t he ethical principles that have
their origin in the Declaration of Helsinki.
Investigators must:
xProvide a copy of the ICF and written information about the study in the language in which 
the participant is most proficient prior to clinical study part icipation. The language must be 
nontechnical and easily understood.
xAllow time necessary for participant or participant‚Äôs legally a cceptable representative to 
inquire about the details of the study.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 86xObtain an ICF signed and personally dated by [CONTACT_35883]‚Äôs legally 
acceptable representative and by [CONTACT_35884] i nformed consent discussion.
xObtain the IRB/IEC‚Äôs written approval/favorable opi[INVESTIGATOR_35811], and after any 
revisions are completed for new information.
If informed consent is initially given by a participant‚Äôs legally acceptable representative or legal
guardian, and the participant subsequently becomes capable of making and communicating his or
her informed consent during the study, consent must additionally be obtai ned from the participant.
Revise the ICF whenever important new information becomes available that is relevant to the
participant‚Äôs consent. The investigator, or a person designated by [CONTACT_093], sh ould fully
inform the participant or the participant‚Äôs legally acceptable representative or legal guardian, of all
pertinent aspects of the study and of any new information releva nt to the participant‚Äôs willingness
to continue participation in the study. This communication should be documented.
The confidentiality of records that could identify subjects must be prote cted, respecting the privacy
and confidentiality rules applicable to regulatory requirements, the participants‚Äô signed ICF and,
in the US, the participants‚Äô signed Health Insurance Portability and Accountability Act (HIPAA)
Authorization.
The consent form must also include a statement that BMS and regulatory auth orities have direct
access to participant records.
Subjects unable to give their written consent (eg, those with stroke or sev ere dementia) may
only be enrolled in the study with the consent of a legally acceptable repre sentative. The participant
must also be informed about the nature of the study to the extent compatible with his or her
understanding, and should this participant become capable, he or she shou ld personally sign and
date the consent form as soon as possible. The explicit wish of a participant who is unable to give
his or her written consent, but who is capable of forming an opi[INVESTIGATOR_35812], or to be withdrawn from, the clinical study at any time should be
considered by [CONTACT_093].
The rights, safety, and well-being of the study participants are the mos t important considerations
and should prevail over interests of science and society.
SOURCE DOCUMENTS
The investigator is responsible for ensuring that the source data are accu rate, legible,
contemporaneous, original, and attributable, whether the data are hand -written on paper or entered
electronically. If source data are created (first entered), modi fied, maintained, archived, retrieved,
or transmitted electronically via computerized systems (and/or any othe r kind of electronic
devices) as part of regulated clinical trial activities, such systems mus t be compliant with all
applicable laws and regulations governing use of electronic records and/ or electronic signatures.
Such systems may include, but are not limited to, electronic medical/heal th records (EMRs/EHRs),
adverse event tracking/reporting, protocol-required assessments, and /or drug accountability
records).
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 87When paper records from such systems are used in place of electronic format to perform regulated
activities, such paper re cords s hould be certified c opi[INVESTIGATOR_014]. A certified co py consists of a copy of
original information that has been verified, as indicated by a dated signa ture, as an exact copy
having all of the same attributes and information as the original.
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by [CONTACT_20444], its vend ors, or the site) must substantiate 
study treatment integrity and traceability from receipt, prepar ation, administration, and through 
destruction or return. Records must be made available for revie w at the request of BMS/designee 
or a Health Authority.
If Then
Supplied by [CONTACT_20444] (or 
its vendors):Records or logs must comply with applicable regulations and gui delines 
and should include:
xamount received and placed in storage area
xamount currently in storage area
xlabel identification number or batch number
xamount dispensed to and returned by [CONTACT_20908], including  
unique participant identifiers
xamount transferred to another area/site for dispensing or storage
xnonstudy disposition (eg, lost, wasted)
xamount destroyed at study site, if applicable
xamount returned to BMS
xretain samples for bioavailabilit y/bioequivalence, if applicabl e
xdates and initials of person responsible for I nvestigational Product 
dispensing/accountability, as per the Delegation of Authority F orm.
Sourced by [CONTACT_3725], and 
not supplied by [CONTACT_35885] 
(examples include 
investigational 
product sourced from 
the site stock or 
commercial supply, 
or a specialty 
pharmacy)The investigator or designee accepts responsibility for documen ting 
traceability and study treatment integrity in accordance with 
requirements applicable under law and the standard operating 
procedures of the sourcing pharmacy.
These records shoul d include:
xlabel identification number or batch number
xamount dispensed to and returned by [CONTACT_20908], including  
unique participant identifiers
xdates and initials of person responsible for Investigational Product 
dispensing/accountability, as per the Delegation of Authority Form.
BMS or designee will provide for ms to facilitate inventory cont rol if the investigational site does not have an 
established system that me ets these requirements.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 88CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are der ived from source documents and 
reported on the CRF must be consistent with the source document s or the discrepancies must be 
explained. Additional clinical information may be collected and  analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for adverse events (AEs) and/or laboratory abnormalities that ar e reported or identified during  the course of the study.
For sites using the Sponsor or designee electronic data capture  (EDC) tool, electronic CRFs will 
be prepared for all data collection fields except for fields specific to serious adverse events 
(SAEs) and pregnancy, which will be reported on the electronic SAE form and Pregnancy 
Surveillance form, respectively. If an electronic SAE form is n ot available, a paper SAE form 
can be used. Spaces may be left blank only in those circumstance s permitted by [CONTACT_3449]-specific 
CRF completion guidelines provided by [CONTACT_35886].
The confidentiality of records t hat could identify participants  must be protected, respecting the 
privacy and confidentia lity rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature [CONTACT_35899]/or corrections on CRFs.The completed CRF and SAE/pregnancy CRFs, must be promptly revi ewed, signed, and dated 
by [CONTACT_20510] a sub-investi gator and who is delegated this task 
on the Delegation of Authority Form. Sub-investigators in Japan  may not be delegated the CRF 
approval task. For electronic CRFs, review and approval/signature [CONTACT_35900]. The investigator must retain a copy of  the CRFs including records 
of the changes and corrections.
Each individual electronically signing electronic CRFs must mee t Sponsor or designee training 
requirements and must only access the BMS EDC tool using the uni que user account provided 
by [CONTACT_35886]. User account s are not to be shared or r eassigned to other individuals
MONITORING
Sponsor or designee representatives will review data centrally to identify potential issues to 
determine a schedule of on-si te visits for targeted review of s tudy records.
Representatives of BMS must be allowed to visit all study site locations periodically to assess 
the data quality and study integrity. On site they will review s tudy records and directly compare 
them with source documents, discuss the conduct of the study wi th the investigator, and verify 
that the facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the 
source documents.
In addition, the study may be evaluated by [CONTACT_35887] d access to CRFs, source documents , other study files, and study 
facilities. BMS audit reports will be kept confidential.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 89The investigator must notify BMS promptly of any inspections sc heduled by [CONTACT_3527], and promptly forward copi[INVESTIGATOR_35813].
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retai n all study records and source 
documents for the maximum period required by [CONTACT_35888], or 
institution procedures, or for the period specified by [CONTACT_35889] d esignee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact [CONTACT_35890].
BMS or designee will notify the investigator (or head of the st udy site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, r etirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee.
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by [CONTACT_20444], a vendor, or sourced by [CONTACT_093]) 
such as partially used study treatment containers, vials, and s yringes may be destroyed on site (as 
applicable; some sites will return unused study treatments depe nding on circumstances).
If Then
Study treatments supplied by 
[CONTACT_20444] (including its vendors)Any unused study treatments supplied by [CONTACT_35891] a nd reconciled by [CONTACT_35892], or to meet local 
regulations (eg, cytotoxics or biologics).
If study treatments will be ret urned, the return will be arrang ed 
by [CONTACT_35893].
Study treatments sourced by [CONTACT_3725], not supplied by [CONTACT_20444] (or 
its vendors) (eg, study 
treatments sourced from the site‚Äôs stock or commercial 
supply, or a specialty 
pharmacy)It is the investigator‚Äôs or designee‚Äôs responsibility to dispos e of 
all containers according to the ins titutional guidelines and 
procedures.
It is the investigator‚Äôs or designee‚Äôs responsibility to arrang e for disposal, provided that procedures 
for proper disposal have been established according to applicab le federal, state, local, and 
institutional guidelines and procedures, and provided that appr opriate records of disposal are kept. 
The following minimal standards must be met:
xOn-site disposal practices must not expose humans to risks from the drug.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 90xOn-site disposal practices and procedures are in agreement with  applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
xWritten procedures for on-site disposal are available and followed. The procedures must be 
filed with the si te‚Äôs SOPs and a copy provided to BMS upon request.
xRecords are maintained that allow for traceability of each cont ainer, including the date 
disposed, quantity disposed, and identification of the person d isposing the containers. The 
method of disposal (eg, incinerator, licensed sanitary landfill , or licensed waste disposal 
vendor) must be documented.
xAccountability and disposal records are complete, up to date, a nd available for the Monitor to 
review throughout the clinical trial period.
It is the investiga tor‚Äôs or designee‚Äôs responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met, the responsible St udy Monitor will make arrangements 
for return of study treatments provided by [CONTACT_20444] (or its vendors) . Destruction of nonstudy 
treatments sourced by [CONTACT_779], not supplied by [CONTACT_20444], is solely the responsibility of the investigator 
or designee.
For sites that will not destroy study treatment on- site, it is the investigator‚Äôs or designee‚Äôs 
responsibility to arrange for disposal of all empty study treatment containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept. The return of full or partially used study treatments supplied by [CONTACT_35894].
CLINICAL STUDY REPORT AND PUBLICATIONS
A signatory investigator must be selected to sign the clinical study report.
For this protocol, the signatory investigator will be selected as appropriate based on one or more 
of the following criteria:
xExternal principal investigator [INVESTIGATOR_35814] (eg, among the top quartile of enrollers)
xInvolvement in trial design
xRegional representation (eg, among top quartile of enrollers fr om a specified region or country)
xOther criteria (as determined by [CONTACT_3476])
The data collected during this study are confidential and propr ietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere t o the publication requirements set 
forth in the clinical trial agreement (CTA) governing study sit e or investigator participation in the 
study. These requirements include, but are not limited to, subm itting proposed publications to 
Sponsor or designee at the earliest practicable time prior to s ubmission or presentation and
otherwise within the time period set forth in the CTA.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 91APPENDIX [ADDRESS_35445] aspartate aminotransferase
AUC area under the concentration-time curve
AUC(0-24) area under the concentration-time curve from 0 to 24 hours
AUC(INF) area under the concentration-time curve extrapolated to infinit y
AUC(TAU) area under the concentration-time curve in one dosing interval
AZA azathioprine
Œ≤-HCG beta-human chorionic gonadotropin
BCRP breast cancer resistance protein
BICLA BILAG-based Composite Lupus Assessment
BID bis in die (twice daily)
BILAG British Isles Lupus Assessment Group
BMS Bristol-Myers Squibb
Cavg average concentration during a dosing interval
CFR Code of Federal Regulations
CI confidence interval
CLASI Cutaneous Lupus Erythematosus Disease Area and Severity Index
Cmax maximum plasma concentration
CMH Cochran-Mantel-Haenszel
CRF case report form
CRS Central Rev iew Services
CS corticosteroid(s)
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 92Term Definition
CTA clinical trial agreement
Ctrough trough observed plasma concentration
CYP450 cytochrome p-[ADDRESS_35446]
HIV human immunodeficiency virus
HRT hormone replacement therapy
hsCRP high-sensitivity C-reactive protein
IB Investigator Brochure
IBD inflammatory bowel disease
IC50 half-maximal inhibitory concentration
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IFN interferon
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 93Term Definition
Ig immunoglobulin
IGRA interferon gamma release assay
IL interleukin
IMP investigational medicinal product
INR international normalized ratio
IP investigational product
IRB Institutional Review Board
IRG interferon-regulated gene
IRT interactive response technology
IV intravenous
JAK Janus kinase
KLH keyhole limpet hemocyanin
LLDAS Lupus Low Disease Activity State
LTE long-term extension
mITT modified intent-to-treat
MMF mycophenolate mofetil/mycophenolic acid
MTX methotrexate
NOAEL no observed adverse effect level
NSAID nonsteroidal anti-inflammatory drug
NYHA [LOCATION_001] Heart Association
OTC over-the-counter
PD pharmacodynamic(s)
PE physical examination
P-gp P-glycoprotein
PK pharmacokinetic(s)
PPS Per Protocol Set
QD quaque die (once daily)
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 94Term Definition
RBC red blood cell
RNA ribonucleic acid
RNP ribonuclear protein
SAE serious adverse event
SAP statistical analysis plan
SLE systemic lupus erythematosus
SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index [ADDRESS_35447] upper limit of normal
UPCR urine protein/creatinine ratio
US/[LOCATION_003] [LOCATION_002] of America
VAS visual analog scale
WOCBP women of childbearing potential
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 95APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP, AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An adverse event (AE) is defined as any new untoward medical oc currence or worsening of a 
preexisting medical condition in a clinical investigation subje ct administered study drug and that 
does not necessarily have a cau sal relationship with this treat ment .
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the us e of study drug, whether or not 
considered related to the study drug.
Events Meeting the AE Definition
xAny abnormal laboratory test results (hematology, clinical chem istry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological sc ans, vital signs 
measurements), including those that worsen from baseline, consi dered clinically s ignificant 
in the medical and scientific judgment of the investigator. Not e that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term  should be updated to be the 
diagnosis.
xExacerbation of a chronic or intermittent preexisting condition  including either an increase 
in frequency and/or intensity of the condition.
xNew conditions detected or diagnosed after study intervention administration even though 
it may have been present before the start of the study.
xSigns, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
xSigns, symptoms, or the clinical sequelae of a suspected overdo se of either study 
interventio n or a concomitant medication. Overdose as a verbatim term (as reported by [CONTACT_1275]), should not be reported as an AE/SAE unless it is  an intentional overdose taken 
with possible suicidal/self-harming intent. Such overdoses shou ld be reported regar dless of 
sequelae and should specify "intentional overdose" as the verba tim term.
Events NOT Meeting the AE Definition
xMedical or surgical procedure (eg, endoscopy, appendectomy): th e condition that leads to 
the procedure is the AE.
xSituations in which a n untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot b e an SAE even if serious conditions 
are met.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 96SERIOUS ADVERSE EVENTS
Serious Adverse Event Definition: Any untoward medical occurren ce that, at any dose:
Results in death
Is life-threatening (defined as an event in which the subject w as at risk of death at the time of 
the event; it does not refer to an event which hypothetically m ight have caused death if it were 
more severe)
Requires inpatient hospi[INVESTIGATOR_20345] (see note 
below)
Note: The following hospi[INVESTIGATOR_35815]: 
xa visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
xelective surgery, planned  prior to signing consent
xadmissions as per protocol for a planned medical/surgical proce dure
xroutine health assessment requiring admission for baseline/trending of health status (eg, 
routine colonoscopy)
xmedical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
xadmission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical intervention (eg, lack of hous ing, economic inadequacy, 
caregiver respi[INVESTIGATOR_040], family circumstances, administrative reason)
xadmission for administration of anticancer therapy in the absen ce of any other SAEs (applies 
to oncology protocols)
Results in persistent or signi ficant disability or permanent da mage
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event[s] th at may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_313], based up on appropriate medical and 
scientific judgment, may jeopardize the subject or may require i ntervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above). Examples 
of such events include, but are not limited to, intensive treat ment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions  that do not result in 
hospi[INVESTIGATOR_059]. Potential drug -induced liver injury (DILI) is also considered an important 
medical event (see  Section 8.3.8 for the definition of potential DILI). 
Pregnancy and potential DILI must follow the same transmission timing and processes to BMS as 
used for SAEs (see Section 8.3.6 for reporting pregnancies).
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 97EVALUATING AES AND SAES
Assessment of Intensity
The intensity of AEs is deter mined by a physician and will use the following levels:
xMild: An event that is easily tolerated by [CONTACT_423], causing minimal discomfort, and not 
interfering with everyday activities.
xModerate: An event that causes sufficient discomfort and interf eres with normal everyday 
activities.
xSevere: An event that prevents normal everyday activities. An A E that is assessed as severe 
should not be confused with an SAE. Severe is a cat egory utilized for rating the intensity 
of an event; and both AEs and SAEs can be assessed as severe.
Assessment of Causality
xThe investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE. A ‚Äúreaso nable possibility of a relationship‚Äù conveys that 
there are facts, evidences, a nd/or arguments to suggest a causa l relationship rather than a 
relationship cannot be ruled out.
xThe investigator will use clinical judgment to determine the re lationship.
xAlter native causes, such as underlying disease(s), concomitant thera py, and other risk 
factors, as well as the temporal relationship of the event to s tudy intervention 
administration, will be considered and investigated.
xThe investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
xFor each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality .
xThere may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to Sponsor. Howeve r, it is very important that 
the investigator always make an assessment of causality for every event before the i nitial 
transmission of the SAE data to Sponsor.
xThe investigator may change his/her opi[INVESTIGATOR_35816]- up information 
and send a SAE follow-up report w ith the updated causality assessment.
xThe causality assessment is one of the criteri a used when determining regulatory reporting 
requirements.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 98Follow-up of AEs and SAEs
If only limited information is initially available, follow-up r eports are required. Note: Follow-
up SAE reports must include the sa me investigator term(s) initi ally reported. 
If an ongoing SAE changes in its  intensity or relationship to s tudy drug or if new information 
becomes available, the SAE report must be updated and submitted  within 24 hours to BMS 
(or designee) using the same proced ure used for transmitting th e initial SAE report.
All SAEs must be followed to resolution or stabilization.
REPORTING OF SAES TO SPONSOR OR DESIGNEE
SAEs, whether related or not related to study drug, and pregnan cies must be reported to  
Drug Safety within [ADDRESS_35448] be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmission to:
SAE Email Address: 
SAE Fax Number: 
Americas: 
Europe/East Asia-Pacific:
SAE Telephone Contact -For questions on SAE/pregnancy reporting, please call:
Americas: 
Europe/East Asia-Pacific: 
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 99APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until beco ming postmenopausal unless 
permanently sterile. Permanent  sterilization methods include hys terectomy, bilateral 
salpi[INVESTIGATOR_1656], and bilateral oophorectomy.
Women in the following categor ies are not considered WOCBP:
xPremenarchal
xPremenopausal female with 1 of the following:
oDocumented hysterectomy
oDocumented bilateral salpi[INVESTIGATOR_35817]: Documentation can come from the site personnel‚Äôs review of the subject‚Äôs medical records, 
medical examination, or medical history interview.
xPostmenopausal female 
oA postmenopausal state is defined as [ADDRESS_35449] a serum follicle-stimulating horm o n e  ( F S H )  l e v e l  
> 40 mIU/mL to confirm menopause.
Note: Women treated with hormone r eplacement therapy (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order  to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout periods below are suggested guidelines and the investigators should use their 
judgment in checking serum FSH levels.
x1 week minimum for vaginal hormonal products (rings, creams, ge ls)
x4 week minimum for transdermal products
x8 week minimum for oral products
Other parenteral products may require washout periods as long a s 6 months. If the serum FSH 
level is > 40 mIU/mL at any time during the washout period, the w oman can be considered 
postmenopausal.
CONTRACEPTION GUIDANCE FOR FEMALE SUBJECTS OF CHILDBEARING 
POTENTIAL
One of the highly effective methods or less than highly effectiv e methods of contraception listed 
below is required during study duration and until the end of re levant systemic exposure, defined 
as 3 days after the end of study treatment, plus 30 days.
Local laws and regulations may require use of alternative and/o r additional contraception methods 
(eg, one highly effective method plus another method).
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 100Highly Effective Cont raceptive Methods Th at Are User-Dependent 
Failure rate of < 1% per year when used consistently and correctly.a
xCombined (estrogen- and progestogen-containing) hormonal contrac eption associated with 
inhibition of ovulation
ooral 
ointravaginal 
otransdermal 
xCombined (estrogen- and progestogen- containing) hormonal contraception must begin at 
least [ADDRESS_35450] be discussed in the 
event that the WOCBP participants chooses to forego complete ab stinence 
NOTES: 
aTypi[INVESTIGATOR_35818]. Use  should be consistent 
with local regulations regarding the use of contraceptive metho ds for participants participating in clinical 
studies.  
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 101bIntrauterine devices and intrau terine hormone-releasing systems  are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exp osures from intrauterine devices do not alter 
contraception effectiveness.
Less Than Highly Effective Contraceptive Methods That Are User- Dependent 
Failure rate of > 1% per year when used consistently and correctly.
xMale or female condom with or without spermicide. Male and fema le condoms cannot be 
used simultaneously
xDiaphragm with spermicide
xCervical cap with spermicide
xVaginal sponge with spermicide
xProgestogen- only oral hormonal contraception, where inhibition of ovulation  i s  n o t  t h e  
primary mechanism of action
Unacceptable Methods of Contraception
xPeriodic abstinence (calendar, symptothermal, post-ovulation me thods)
xWithdrawal (coitus interruptus).
xSpermicide only
xLactation amenorrhea method
CONTRACEPTION GUIDANCE FOR MALE SUBJECTS WITH FEMALE 
PARTNER(S) OF CHILDBEARING POTENTIAL 
Male subjects with female partners of childbearing potential are eligible to participate if they agree 
to the following during the treatment:
xInform any and all partner(s) of their participation in a clini cal drug study and the need to 
comply with contraception instructions as directed by [CONTACT_8647].
xCondom use is not required.
xFemale partners of men participating in the study to consider u se of effective methods of 
contraception until the end of relevant systemic exposure, defined as the duration of the study 
treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is provided in Section 8.3.6 .
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 102APPENDIX 5 SYSTEMIC LUPUS INTERNATIONAL COLLABORATING
CLINICS CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS
ERYTHEMATOSUS
*Notes:
CLINICAL CRITERIA
1)Acute Cutaneous Lupus OR Subacute Cutaneous Lupus
oAcute cutaneous lupus: lupus malar rash (do not count if malar discoid), bullous lupus,
toxic epi[INVESTIGATOR_35819], maculopapular lupus rash, photosensitive lupus
rash (in the absence of dermatomyositis)
oSubacute cutaneous lupus: nonindurated psoriaform and/or annula r polycyclic lesions that
resolve without scarring, although occasionally with postinflam matory dyspi[INVESTIGATOR_35820])
2)Chronic Cutaneous Lupus
Classic discoid rash localized (above the neck) or generalized (above and below the neck),
hypertrophic (verrucous) lupus, lupus panniculitis (profundus), mucosal lupus, lupus
erythematosus tumidus, chilblains lupus, discoid lupus/lichen p lanus overlap
3)Oral Ulcers OR Nasal Ulcers
oOral: palate, buccal, tongue
oNasal ulcers
oIn the absence of other causes, such as vasculitis, Beh“´et‚Äôs di sease , infection (herpes virus),
inflammatory bowel disease, reactiv e arthritis, and acidic food s
4)Nonscarring Alopecia
Diffuse thinning or hair fragili ty with visible broken hairs, i n the absence of other causes such 
as alopecia areata, drugs, i ron deficiency, and androgenic alope cia
5)Synovitis Involving [ADDRESS_35451] 30 minutes of mo rning stiffness
6)Serositis
xTypi[INVESTIGATOR_35821] [ADDRESS_35452] eural rub
xTypi[INVESTIGATOR_35822] (pain with recumbency improved by [CONTACT_35895]) for more 
than 1 day OR pericardial effusion OR pericardial rub OR perica rditis by 
[CONTACT_35896], such as infection, ur emia, and Dressler‚Äôs pericarditis
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 1037)Renal
Urine protein ‚Äìto-creatinine ratio (or 24-hour urine protein) representing 500 m g protein per 
24 hours OR red blood cell casts
8)Neurologic
Seizures, psychosis, mononeuritis multiplex (in the absence of other known causes such as 
primary vasculitis), myelitis, peripheral or cranial neuropathy (in the absence of other known 
causes such as primary vasculitis, infection, and diabetes mellitus), acute confusional state (in the absence of other causes, including toxic/metabolic, uremia,  drugs)
9)Hemolytic Anemia
10) Leukopenia (< 4000/mm3) OR Lymphopenia (< 1000/mm3)
Leukopenia at least once: In the absence of other known causes such as Felty‚Äôs syndrome, drugs, 
and portal hypertension.
Lymphopenia at least once: in the absence of other known causes  such as corticosteroids, drugs, 
and infection
11) Thrombocytopenia (< 100,000/mm3)
At least once in the absence of other known causes such as drug s, portal hypertension, and 
thrombotic thrombocytopenic purpuraIMMUNOLOGIC CRITERIA
1)ANA level above laboratory reference range
2)Anti-dsDNA antibody level above laboratory reference range (or 2-fold the reference range if 
tested by [CONTACT_28745]-linked immunosorbent assay [ELISA]); indetermi nate results are considered 
positive
3)Anti-Sm : presence of antibody to Sm nuclear antigen
4)Antiphospholipid antibody positivity, as determined by
[CONTACT_35897]-positive test result for rapid plasma reagin (RPR)
xMedium- or high-titer anticardiolipin antibody level (IgA, IgG, or IgM)
xPositive test result for anti ‚Äì2-glycoprotein I (IgA, IgG, or IgM)
5)Low complement (C3, C4, or CH50)
6)Direct Coombs test (in the absence of hemolytic anemia)
Source:
Petri M, Orbai AM, Alarcon GS, et al. Derivation of the Systemi c Lupus International 
Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 
2012 Aug;64(8):2677-86.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 104APPENDIX 6 COMMONLY USED CORTICOSTEROID EQUIVALENTS
Medication Dose Equivalence
Prednisone 20 mg
Cortisone 100 mg
Hydrocortisone 80 mg
Prednisolone 20 mg
Methylprednisolone 16 mg
Triamcinolone 16 mg
Budesonide 4 mg
Dexamethasone 3 mg
Betamethasone 2.4 mg
Deflazacort 26 mg
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 105APPENDIX 7 REQUIRED RECOVERY (WASHOUT) TIMES FOR SPECIFIC 
MEDICATIONS PRIOR TO SCREENING
Medications Discontinuation Prior to Signing 
Consent
Abatacept (CTLA4Ig) 12 weeks
Acthar¬Ægel (repository corticotropin injection) [ADDRESS_35453] 4 weeks
Atacicept (TACI-Ig) 48 weeks
Belimumab 24 weeks
BIIB059 15 weeks
Certolizumab pegol 24 weeks
Cyclophosphamide 24 weeks
Cyclosporine 4 weeks for systemic use (oral, IV, etc)
Danazol 4 weeks
Dapsone 4 weeks
Eculizumab 12 weeks
Efalizumab 8w e e k s
Epratuzumab 18 weeks
Etanercept 4 weeks
Infliximab 12 weeks
Intravenous globulin 4 weeks
Leflunomide 36 weeks
Lenalidomide with cholestyramine 24 weeks
Lulizumab 6 weeks
Lupuzor (IPP-201101) 12 weeks
Memantine 4 weeks
Natalizumab 12 weeks
Obinutuzumab 26 weeks
Ocrelizumab 24 weeks
Ofatumumab 26 weeks
Plasmapheresis 24 weeks
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 106Medications Discontinuation Prior to Signing 
Consent
Retinoids (oral isotretinoin, and acitretin; topi[INVESTIGATOR_35823])4 weeks
Rituximab 24 weeks
Sifalimumab 26 weeks
Sirolimus 4 weeks
Sulfasalazine 4 weeks
Tabalumab 14 weeks
Tacrolimus 4 weeks for systemic use (oral, IV, etc)
Thalidomide 4 weeks
Tocilizumab 12 weeks
Tofacitinib 4 weeks
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 107APPENDIX 8 DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS IV
Alcohol abuse:
In the past year, have you:
xFound that drinking ‚Äìor being sick from drinking ‚Äìoften interfered with taking care of your 
home or family? Or caused job troubles? Or school problems?
xMore than once gotten into situations while or after drinking t hat increased your chances of
getting hurt (such as driving, swimming, using machinery, walki ng in a dangerous area, or 
having unsafe sex)?
xMore than once gotten arrested, been held at a police station, or had other legal problems 
because of your drinking?
xContinued to drink even though it was causing trouble with your  family or friends? 
The presence of any 1 of the above is considered indicative of alcohol abuse.
Alcohol dependence:
In the past year, have you:
xHad to drink much more than you once did to get the effect you want? Or found that your usual 
number of drinks had much less effect than before?
xFound that when the effects of alcohol were wearing off, you had withdrawal symptoms, such 
as trouble sleepi[INVESTIGATOR_007], shakiness, restlessness, nausea, sweating,  a racing heart, or a seizure? Or 
sensed things that were not there?
xHad times when you ended up drinking more, or longer, than you intended?
xMore than once wanted to cut down or stop drinking, or tried to , but couldn‚Äôt?
xSpent a lot of time drinking? O r being sick or getting over oth er aftereffects?
xGiven up or cut back on activities that were important or inter esting to you, or gave you 
pleasure, in order to drink?
xContinued to drink even though it was making you feel depressed or anxious or adding to another health problem? Or after having had a memory blackout?
The presence of any 3 of the above is considered indicative of alcohol dependence.
National Institutes of Health, National Institute on Alcohol Ab use and Alcoholism. Alcohol use 
disorder: a comparison between DSM-IV and DSM-5. NIH Publication  No. 13-7999. Reviewed 
July 2016.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 108APPENDIX [ADDRESS_35454] ive hepatitis B infection. For this 
reason, to fully evaluate a participant‚Äôs eligibility for enrollment, the exclusion criterion (see 
Section 5.2 ) requires interpretation of data from [ADDRESS_35455] tests for hep atitis B, ie, measurement 
of hepatitis B surface antigen (HBsAg), hepatitis B core antibo dy (anti-HBc), and hepatitis B 
surface antibody (anti-HBs).
The participant‚Äôs eligibil ity for enrollment should be ass essed as described below:
xHepatitis B serological test ne gative (neg) for all results may  be included in the study
xHBsAg (neg), anti-HBc (neg), and anti-HBs positive (POS) may be included in the study 
(immunized due to hepatitis B vaccination)
xHBsAg (neg), anti-HBc (POS), and anti-HBs (POS) are to be exclud ed from the study (immune 
due to natural infection exposure)
xParticipants that are HBsAg (POS ) are excluded from the study ( acute or chronic infection)
xParticipants that are anti-HBc (POS) are excluded from the stud y (acute or chronic infection)
xParticipants that are HBsAg (neg), anti-HBc (POS), and anti-HBs  (neg) are to be excluded 
from the study (interpretation unclear)
Please refer to the schematic ‚ÄúInterpretation of Hepatitis B Se rologic Test Results‚Äù (below) 
provided by [CONTACT_9092], Center s for Disease Control and 
Prevention.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 109
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 110APPENDIX 10 BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX ‚Äì2004
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 111Sources:
Isenberg, DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an 
updated version of the British Isles Lupus Assessment Group‚Äôs d isease activity index for patients 
with systemic lupus erythematosus. Rheumatology (Oxford) 2005;4 4(7):902-6.
Yee CS, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 2004 
Index - A Reliable Tool for Assessment of Systemic Lupus Erythematosus Activity. Arthritis 
Rheum 2006;54:3300 ‚Äì05.
Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid 
for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 
2007;56(12):4113-19.
Yee CS, Cresswell L, Farewell V, et al: Numerical scoring for t he BILAG-2004 index. 
Rheumatology (Oxford) 2010 Sep;49(9):1665-9.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 112APPENDIX 11 SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY 
INDEX 2000 DISEASE ACTIVITY QUESTIONNAIRE
Note: Detailed definitions of the individual items are included  in a quick reference guide for sites.
For an item to be scored the indicated weight, the manifestatio n must have been present in the past 
30 days.
The glossary of the terms is adjacent on the form itself.
Enter weight in SLEDAI-2K Score column if descriptor is present  at the time of the visit or in the 
preceding 30 days.Sources:
Gladman, DD., Iba√±ez, D., Urowitz, MB. Systemic Lupus Erythematosus Disease Activity Index 
2000. J Rheumatol 2002;29:288-91.
Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window.  Lupus 2010;19:49-51.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 113
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 114APPENDIX 12 CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND 
SEVERITY INDEX (CLASI)
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 115Sources:
Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lu pus Erythematosus Disease Area 
and Severity Index): An outcome  instrument for cutaneous lupus erythematosus. J Invest Dermatol 
2005;125:[ADDRESS_35456] ivity and damage in patients with 
cutaneous lupus erythematosus. Arch Dermatol 2008;144(2):173-80 .
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 116
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 117
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 118
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 119
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 120
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 121
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 122
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 123
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 124
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 125
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 126
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 127
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 128APPENDIX 17 OTHER ASSESSMENTS
Physician‚Äôs Global Assessment of Disease Activity
How do you assess your patient‚Äôs (the subject‚Äôs) current diseas e activity as compared to the last
visit? Please mark the line below.
Patient‚Äôs Global Assessment of Disease Activity
Considering all the ways in which your lupus has affected you i n the PAST WEEK, please make
a mark on the line below to show how you are doing.
Very Poorly Very Well
Patient-Reported Pain Assessment
On a scale of [ADDRESS_35457] WEEK?
Please circle the number below that represents your pain.
Approved 1.0 v
Approved
1.0
v
Clinical Protocol IM011021
BMS-986165 TYK2 Inhibitor
15-Apr-2020; Revised Protocol 04, Final Approved
BMS Confidential 129APPENDIX [ADDRESS_35458] is not 
exhaustive, and the 30 mg morphine equivalence limit applies to all opi[INVESTIGATOR_35824].
Opi[INVESTIGATOR_2480] 30 mg morphine equivalent
butorphanol 4.3 mg/day
codeine 200 mg/day
dihydrocodeine 120 mg/day
fentanyl transdermal 12.5 mcg/hr
hydrocodone 30 mg/day
hydromorphone 7.5 mg/day
levorphanol tartrate 2.7 mg/day
meperidine HCl 300 mg/day
oxycodone 20 mg/day
oxymorphone 10 mg/day
pentazocine 81.1 mg/day
tapentadol 75 mg/day
tramadol 300 mg/day
Reference: 
Centers for Medicare and Medicaid  Services. Opi[INVESTIGATOR_35825] e Milligram Equivalent 
Conversion Factors. https://www.cms.gov/Medicare/Prescription-Drug-
Coverage/Pre
scriptionDrugCovContra/Downloads/Opi[INVESTIGATOR_2480]-Morphine-EQ -Conversion-Factors-
Aug-2017.pdf . Accessed 04-Jun-2019.
Approved 1.0 v
Approved
1.0
v